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Chioroquine-resistance was studied in the rodent malaria parasite, 
Plasmodium. chabaudi. 	Parasite lines exhibiting different degrees of 
resistance were obtained by submitting a line already resistant to a low 
level of the drug to a gradual increase of drug pressure. 	The 
chloroquine-resi st ant lines were found to be stable after mosquito 
transmission and after multiple blood passage in the absence of the 
drug. 	The inheritance of the high level of chloroquine-resistance 
(resistant to 30 mg kg- 
1 
 chloroquine for 6 days) was examined by 
crossing this resistant line with a drug sensitive (sensitive to 3 mg 
kg- 
1 
 chloroquine for 6 days) line. 	The progeny of the cross showed 
intermediate levels of chloroquine-resistance suggesting that the high 
level of resistance was due to more than one mutation. 	Competition 
studies between different lines of P. chabaudi revealed that the highly 
resistant line was at a selective advantage over the sensitive forms 
and that cross products were favoured over parental resistant lines. 
A mefloquine-resistant line was established by a gradual increase 
in drug pressure. 	This resistance was variable in its stability after 
mosquito transmission and after blood passage without drug pressure. 
A clone was obtained which was stable on blood passage in the absence 
of the drug (to 15mg kg- 1 Mefloquine for 4 days). 
VII. 
SUMMARY 
Chioroquine-resistance has been studied in the rodent malaria 
parasite Plasmodium chabaudi. 	Parasite lines exhibiting 
different degrees of resistance were obtained by submitting a 
line already resistant to a low level of the drug to a gradual 
increase of drug pressure. 
Lines showing different levels of chloroquine-resistance were 
produced; low (3CQ) intermediate (15CQ) and high (30CQ) 
These levels could be distinguished by drug tests using varying 
doses of chioroquine and by using other drugs to which chloro-
quine appeared to be cross-resistant; these included mefloquine, 
mepacrine and quinine. 
Tests using chloroquine administered for four and six days were 
compared. 	These experiments indicated that the duration of 
drug treatment as well as the dose administered was important for 
antimalarial activity. 	Chloroquine administered at a high dose 
-1 (30 mg Kg ) for four days did not eliminate chloroquine-sensitive 
parasites whereas lower doses administered for six days did 
eradicate chloroquine-sensitive parasites. 
The chloroquine-resistant lines selected were found to be stable 
after mosquito transmission and after multiple blood passage in 
the absence of the drug. 
The inheritance of the high level of chioroquine resistance (30Q) 
was examined by crossing this resistant line with a drug sensitive 
line. 	These two lines were polymorphic for two enzyme markers 
VIII. 
and differed in their response to pyrimethamine. 	The progeny 
of the cross were cloned and each clone was examined for drug 
response and enzyme types. 	Clones which were classified as 
sensitive (to 3 mg Kg_ 
1 
 for 6 days), intermediate (3Q) or 15 
CQ) or highly resistant (30cQ) were detected. 	The presence 
of clones showing intermediate levels of chloroquine resistance 
suggested that the high level (30Q) was due to more than one 
mutation. 	Blood mixtures of the highly resistant (30CQ). and 
the drug sensitive line did not generate parasites with inter-
mediate levels of chioroquine-resistance. 
In vitro chioroquine drug tests were conducted using a chloroquine-
sensitive and the highly resistant (30cQ) lines. 	In the 
presence of chloroquine, the resistant parasites formed vacuoles 
and their development appeared to be arrested at a specific stage 
whereas sensitive parasites continued to develop in the presence 
of the drug forming parasites which appeared abnormal. 	Ino- 
culations from cultures into uninfected mice revealed that the 
resistant parasites remained viable at all but the highest of the 
doses of chloroquine used whereas the sensitive parasites showed 
a reduced viability after exposure to the drug. 
Competition studies were carried out in which known proportions 
of two lines differing in specific characters were injected into 
mice. 	After varying periods of time the infections were 
examined to determine whether the proportions of each line had 
changed. 	The highly resistant (30Q) 	line appeared to possess 
a selective advantage in competition with the chloroquine-
sensitive line from which it was derived. 	However, in 
Ix. 
competition with the chloroquine-sensitive line used in the 
cross the 30'Q line appeared to grow as well as the sensitive 
line; neither line was at a selective advantage. 	A highly 
resistant clone derived from the progeny of the cross was at 
a selective advantage over the parental (30CQ) highly resistant 
line obtained by selection. 
A mefloquine-resistant line was established by a gradual increase 
in drug pressure. 	This line was resistant to a high level of 
the drug (30MF). 
This mefloquine-resistant line appeared to lose its resistance 
after multiple blood passage in the absence of the drug; al-
though the parasites survived the treatment, they emerged pro-
gressively later following drug treatment. 	After mosquito 
transmission, a lower level of mefloquine-resistance (15MF) was 
obtained. 
The resistance of the lower level of resistance (1511F) was 
variable in Its stability after mosquito transmission. 	In one 
case the parasites seemed unstable, after a separate mosquito 
transmission the line was stable in its resistance; this resist-
ance was stable after blood passage in the absence of the drug. 
I . 
1. 	INTRODUCTION 
1.1 The Malaria Problem 
The worldwide malaria morbidity is at least one hundred million 
cases per year; the mortality, although considerably lower is still 
about one million; most of those affected are the young. 	At present 
21 per cent of the world's 2,048 million people who live in malarious 
areas are in countries from which malaria has been eradicated. 	Some 
62 per cent are living where antimalarial measures are being applied. 
Nevertheless, there are still about 352 million people living in places 
where no antimalarial control activities are being undertaken (WHO, 
1976; Wernsdorfer, 1979). 
In several Asian countries malaria has come back to territories 
from where it was once eradicated and there is little indication that 
this trend will not continue. 	This may be partly due to problems of 
migration (Bruce-Chwatt, 1970, 1973) as well as increasing problems 
with chemotherapy. 
In the absence of a vaccine, chemotherapy has been the only 
practical measure we have had against malaria, especially against the 
most important human species, Plasmodium falciparum. 	Reviews by the 
World Health Organization (WHO) Scientific Groups (1967, 1973) emphasise 
the role drugs play in the control and eradication of malaria in 
endemic areas. The development of drug resistance to chemotherapy 
has obviously been of great concern. 	The eradication programmes using 
insecticides against the vector and antimalarial drugs against the 
parasite have been retarded by the diminishing effects of these 
chemicals due to the increasing development of drug resistance. 
Drug resistance has been in existence for some time. 	It was 
predicted that at least in the case of trypanosomes, resistance to 
any type of drug active against them could arise (Ehrlich, 1910). 
This belief is certainly true of antimalarial drugs where resistance 
to all existing antimalarial drugs has been developed either in nature 
or in laboratories (see reviews by Peters, 1970, 1974). 
There are several definitions of drug resistance. 	In order that 
comparative tests can be undertaken throughout the world, the WHO 
(1965, 1973) defined resistance as a "drug-parasite interaction in 
which there is the ability of a parasite strain to survive and/or 
multiply despite the administration and absorption of the drug given 
in doses equal or higher than those usually recommended, but within 
the limits of tolerance of the subject". 	In other words the parasite 
loses its sensitivity to the drug by a change in the parasite rather 
than the host. 	Any alteration in the host's mechanisms are presumed 
to be parasite mediated. 
The increased incidence of drug resistant malaria in the Far East 
prompted massive drug screening programmes by the United States of 
America in the 1960s in view of their military involvement in the area. 
Malaria to American soldiers in Vietnam was as devastating as wounds 
from action (Tigert, 1966). 	These drug screening programmes have re- 
sulted in new compounds which are currently undergoing trials (Schmidt, 
1978). 	In addition to drug screening there hasbeen increasing 
interest in the study of the underlying mechanism of drug resistance 
which has stimulated research on the biology of the parasite at various 
levels, using a variety of techniques. 
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1.2 	Life cycle 
The life cycle of rodent malaria is summarised in Figure 1. 
The parasite undergoes a cyclical development which involves an 
asexual phase in a mammal and a sexual phase in the insect vector. 
In the mammalian host two cycles of division occur, tissue schizogony 
(exoerythrocytic, which takes place in the liver) and blood schizogony 
(erythrocytic). 	An infection is initiated by the inoculation of 
sporozoites into the blood by infected female mosquitoes (1). 	Liver 
parenchyma cells are invaded by sporozoites(2)which then develop into 
schizonts by nuclear division(3).The schizonts mature (42 - 72 hours 
after mosquito bite) releasing between 2,000 - 20,000 merozoites into 
the blood stream (4). 	The time of exoerythrocytic schizogony varies 
from one species to another (Garnham, 1966). 	Merozoites can either 
invade erythrocytes (5a) or undergo secondary exoerythrocytic cycles 
of development in the liver (5b, 2-4). 	Merozoites which invade erythro- 
cytes form trophozoites (6) which mature, undergoing several nuclear 
divisions to form schizonts (7). 	The schizonts contain several mero- 
zoites which vary in number from species to species (4-18 in murine 
plasmodia); these merozoites are released following the breakdown of 
the host cells (8). 	Some merozoites reinvade other red blood cells, 
thus continuing the asexual cycle in the blood (5a). 	Alternatively, 
some merozoites develop sexual forms called macro-and microgametocytes 
(9b). 	It has been shown that merozoites from hepatic schizonts can 
develop directly into gametocytes (5c) (Killick-Kendrick & Warren, 
1968). 
T  the midgut of the insect host the gametocytes give rise to 
the female (macro-) gamete while the male (micro-) gametocyte undergoes 
exflagellation liberating the male (micro-) gamete which fertilizes 
am 
the female gamete (10 & 11). 	Exflagellation is a process whereby 
the motile microgametes are formed; the microgametes lash about con-
tinuously and one by one break away from the parent body. 	This takes 
between 10 - 30 minutes according to species and environmental temper- 
ature. 	The zygote formed following fertilization is called an 
ookinete (12) , which penetrates the midgut wall of the mosquito to 
form an oocyst. 	On the outside of the midgut the ookinete develops 
into an oocyst (13) which matures over a period of 8 - 15 days de- 
pending on environmental temperatures, forming sporozoites. 	The number 
of sporozoites varies according to species from more than 1,000-10,000 
(Garnham, 1966). When mature, the sporozoites are liberated into the 
body cavity (14) from which they migrate to the salivary glands where 
they accumulate before being injected into another mammalian host when 
the female mosquito again feeds (1). 
1.3 Antimalarial Drugs 
There are numerous reviews on drug resistance in Protozoa, e.g. 
1963, 
Bishop, 1958; Schnitzer,/1966. 	Drug resistance in Plasmodia has 
been reviewed by many authors including Schmidt, 1969; Peters, 1970, 
1974; Warhurst, 1973; Carter & Diggs,1977. 
There are five main groups of antimalarial drugs. These are: 
Quinine, inepacrine and 4-Aminoquinolines, e.g. chloroquine, 
4-Quinoli ne methanols, e.g. mefloq ulne. 
8-Aminoquinolines, e.g. primaquine. 
Sulpionamides, e.g. sulphadiazine. 
Antifolates, e.g. pyrimethamine,proguaniL 
5. 
These drugs share general structural similarities and mechanisms 
of antimalarial action. 	They also overlap in the area of attack in 
the parasite life cycle. 	The first class which includes quinine and 
chloroquine are almost without effect against sporogonic and pre- 
erythrocytic stages. 	However, they act against the asexual blood 
parasites and are hence referred to as blood schizontocides, inhibiting 
blood schizogony. 	The 8-aminoquinolines are effective against all 
stages of the parasite including the liver forms. 	The sulphonamides 
and antifolates are effective against actively dividing parasites. 
These drugs are therefore active against all stages of the parasite 
life cycle except gametocytes. 	4-Quinolinemthanols are active against 
asexual blood forms; there is no- evidence for activity against pre-
erythrocytic stages of the parasite. 
Reports of drug resistance refer to resistance of blood forms of 
the parasite. 	Drug resistance to the first four classes are prevalent 
(see reviews above). 	This investigation is mainly concerned with drug 
resistance involving the 4-aminoquinoline, chioroquine and the 4- 
quinolinemethanol, mefloquine. 	Pyrimethamine-resistance is used as a 
marker for genetic analyses. 
1.4 Drug Resistance in Human Malaria 
There are four main species of malaria parasites; these are: 
P. falciparum, P malariae, P. ovale and P. vivax. 	These four human 
species of malaria parasites show variation in their response to drugs 
(Peters, 1970). 	Chioroquine-resistance at present only concerns P. 
falciparum. 	As chloroquine-resistance has only recently emerged in 
Africa, these strains may differ from their Far Eastern or South 
American counterparts where chioroquine-resi st ant strains are widespread. 
In contrast, resistance to other drugs such as proguanil and pyri-
methamine has arisen rapidly and is widespread. 	Four years after its 
introduction proguanil-resistance emerged (Field & Edeson, 1949) and 
only two years after its use resistance was widespread. 	The first 
report of pyrimethamine- resistancewas in 1952 (McGregor & Smith, 1952), 
the same year as its first use in the field. 	Many reports of pyri- 
methamine-resistance followed (summarised by Peters, 1970). 
Chloroquine-resistance was first suspected in 1960 in Venezuela 
(Maberti, 1960). 	The first confirmed case of chloroquine-resistance in. 
P. falciparum was from Colombia in 1961 (Moore & Lanier, 1961; Young & 
Moore, 1961). 	This was followed by other reports from the Far Est 
(Young et al. , 1963; Montgomery & Eyles, 1963; Eyles et al. , 1963; 
Powel et al. , 1964; Harinasuta, 1965; Sandoshamet al. , 1966; Ebisawa 
& Fukuyama, 1975; Hall et al., l975a). 	It has spread as far as Sabah 
(Clyde et al., 1973b), the Philippines (Clyde et al., 1971; Ramos et al., 
1971; Shute et al. , 1972; Valera & Shute, 1976), Indonesia (Clyde et 
al., 1976a), Australasia (Simpson & Williams, 1978) and as far West as 
Rangoon in Burma (Clyde et al., 1973a). 	Reports of chloroquine- 
resistant P. falciparum from South America also followed (da Silva et 
al., 1961; Rodrigues, 1961; Box et al., 1963; Godoy et al., 1975). 
Several claims of chloroquine-resistance in Africa have been made 
(Schwendler, 1965; Lasch & N'Guyen, 1965; Jeffrey & Gibson, 1966; 
Stevenson, 1966; Hipoo & McCallum, 1967; Beausoleil, 1968; Wolfe & 
Huddleston, 1969; Ricosse et al., 1969; Bruce-Chwatt, 1974). 
However, the tests used did not meet the WHO criteria for drug re- 
sistance and were therefore unconfirmed. 	Studies by Dennis et al. 
(1974) on an Ethiopian strain, Ansdell et al. (1974) on a Nigerian 
strain, a case report by Pillay & Bhoola (1975) in 
7. 
South East Africa, a review by Olatunde (1977) and studies by Kahn & 
Maguire (1978), although unconfirmed indicate that chioroquine-
resistant P. falciparum may exist in Africa. 	Recent confirmed case 
reports of chloroquine-resistant P. falciparum from Kenya supports this 
view (Fogh, 1979; Stille, 1979). 
Although chioroquine-resistance did not appear for more than a 
decade after its use for therapy in 1945, once developed it has spread 
rapidly throughout parts of the world and its progress is anxiously 
being followed into Africa which, until recently,had been free of 
chloroquine-resistance. 	Warnings of the possibility of the develop- 
ment of chloroquine-resistance came as early as 1946 (Most et al., 1946) 
and 1948 (Earle & Berliner, 1948). 	The latter authors had forseen the 
possibility of developing chioroquine-resistant P. falciparum by using 
low doses of the drug which were active against another human malaria 
species P. vivax but were less effective against P; falciparum. 	As 
shown by work with rodents (Rosario, 1976a,b) this would be analogous 
to selection for resistance using a low pressure method. 	Unwittingly 
ideal conditions for the selection of chioroquine-resistant P. falciparurn 
had been present. 
1.5 	Chloroquine-resistance in the Laboratory 
In the primary screening of drugs in vivo, animals provide us with 
a useful tool. 	Rodent malaria is a good model for the demonstration 
of blood schizontocidal action and avian systems are useful in the 
study of causal prophylactic activity (see review by Peters, 1970, 1974). 
The adaptation of the human malaria P, falciparum to the owl monkey has 
resulted in a valuable model for the evaluation of more promising 
8. 
compounds (see reviews by Schmidt, 1969, 1973, 1978). 	Schmidt (1978) 
showed that this host offers a possible model for human malaria. 
Chloroquine-resistant strains of P. falciparum were classified and 
fourteen potential antimalarial drugs were tested. 	This work on P. 
falciparum and P. vivax infections in the owl monkey (Schmidt, 1978) 
will probably never be repeated due to the large numbers of animals 
used. 
The first report of chloroquine-resistance in a malaria parasite 
was in 1956 in the avian species P. gallinaceum (Ray & Sharma, 1956) and 
in the rodent species P. berghei (Ramakrishnan et al., 1957). 	Both 
sets of authors used a low pressure method to induce resistance; this 
involved selection using a low drug dose and prolonged passaging under 
drug pressure. 	There have also been numerous attempts to select for 
chioroquine-resistance in various malaria species which have been un-
successful (Thompson et al., 1948 with P, lophurae; Seaton, 1951; 
Bishop & McConnachie, 1952 with the avian P. glinaceum; Kollert, 
1963 with P, relictuin; Schmidt et al., 1949 with P. cynomolgi). 
A great number of studies have been undertaken using rodent malaria 
species. 	Unlike simian models, rodents are readily available at low 
costs and large numbers which render them the most suitable laboratory 
model. 	The four species of rodent malaria have innate differences in 
their response to chloroquine as follows: 
P. yoelii - This species is naturally resistant to high doses of 
chloroquine (Warhurst & Killick-Kendrick, 1967; Peters, 1968c; Carter, 
1972). 
P. berghei - This species is usually sensitive to chloroquine. 
Resistance to chloroquine has been obtained by a variety of means. 	A 
9. 
low pressure method was used by Ramakrishnan etal. (1957) , Kollert 
(1963), Peters (1965) and Jacobs (1965). 	High doses were used by 
Sautetetal. (1959) and Benazet (1965). 	Hawking and Gammage (1962) 
selected for resistance by blocking the immune system of the host and 
by adding drug in the diet.  
Another method attempted by Hawking 
(1966) involved the administration of a single high dose to mice with 
high parasitaemias; shortly after drug treatment (1 and 5 hours) the 
animals were exsanguinated and the blood inoculated into clean mice. 
However, this procedure was unsuccessful in producing resistance. 
It must be stressed that the chloroquine-resistant lines obtained 
have mainly been unstable in the absence of the drug (Ramakrishnan et 
al., 1957; Kollert, 1963; Jacobs, 1965;, Thompson et al., 1965; 
Peters, 1965; Hawking, 1966), 	Peters (1968a,b,c) has carried out 
studies of the loss of chioroquine-resistance during blood and mosquito 
passage. 	The occurrence of a stable resistant line in P. bergheide- 
veloped by Peters et al. (1969) was later found to be a subspecies of 
P. yoelii (Peters et al., 1978) which is naturally resistant to the drug. 
P. vinckei - This species is naturally sensitive to chloroquine. 
Only one successful report of the development of stable chloroquine-
resistance in this species has been reported by Powers et al. (1969). 
Using a low pressure method a line resistant to chloroquine was esta-
blished from a strain which was already resistant to pyrimethainine. 
P. chabaudi - Peters (1970) has shown that this species has a 
similar sensitivity to chloroquine as P berghei. 	The only previous 
10. 
report of stable chioroquine-resistance before the work presented 
here is that of Rosario (1976a,b). 
The development of in vitro culture techniques for drug tests is 
likely to provide a quick and easy assay in field work. 	Recent 
developments include a microtechnique (Rieckznann et a].., 1978) which 
is a refinement of earlier attempts (Rieckmann et a].. , 1968). 	Earlier 
short term culture techniques enabled various workers to study new 
drugs (Trager, 1971; Gutteridge et al. , 1972; Siddiqul eta].., 1972). 
One of the most significant developments Is that of the continuous 
culture in vitro of human malaria parasites (Trager & Jensen, 1976; 
Jensen & Trager, 1978). 	Drug tests using parasites from con- 
tinuous cultures have already started (Richards & Maples, 1979), which 
indicate that chloroquine-resistant parasites can be distinguished 
from sensitive forms by these methods. 	A study by Nguyen-Dinh and 
Trager (1978) suggests that an African strain of P. falciparum has the 
genetic capability to develop chloroquIne-resistance. 	They used a 
continuous cultivation method to select for a level of chloroquine-
resistance in P. falciparum comparable to the naturally occurring re-
sistant strains in South East Asia. 
1.6 	Cliloroquine-Mode of Action and Mechanism of Resistance 
Extensive studies have been done to investigate the mechanism of 
action of chloroquine and it has been shown to inhibit a very wide range 
of functions including nucleic acid and protein synthesis as well as 
respiration (Schellenberg & Coatney, 1961; Van Dykeetal., 1969; 
'Gutteridge et al., 1972; Theakston et a].., 1972). 	Three main sites 
of action have been proposed:- 
11. 
DNA and RNA directly or on synthesis. 
Inhibition of proteolytic enzymes/stimulation of autophagic 
vacuole formation. 
Inhibition of oxidative metabolism. 
There is evidence that chloroquine binds or interacts with DNA 
(Allison et al,, 1965; Cohen & Yielding, 1965; Hahn et al., 1966; 
Gutteridgeet al., 1972). Chloroquine also binds to polynucleotides 
(Blodgett & Yielding, 1968; Morris et al., 1970). 	It has been shown 
to degrade large species of rRNA of P. knowlesi (Warhurst & Williamson, 
1968). 	It has been suggested that RNA is rendered more sensitive to 
hydrolysis by ribonucleases when bound to chloroquine (Wichard & Holbrook, 
1970). 	In addition, the drug inhibits nucleic acid and protein synthesis 
(Warhurst, 1969; Gutteridge & Trigg, 1972; Warhurst et al., 1972). The 
ease with which chloroquine interacts with nucleic acids has led a number 
of workers to conclude that this is the basis of their antimalarial 
action. 	However, chloroquine has a similar affinity for the DNA of P. 
knowlesj and its host (Gutteridge et al.,, 1972). 	Furthermore, the host 
and parasite nuclear chromatin structure and composition of rodent malaria 
parasites have been found to be similar(Bahr & Mikel, 1972). 	Therefore 
the primary action of chloroquiñe is unlikely to be at this level, al-
though it may be the site of lethal action. 
Chloroquine induces pigment clumping and autophagic vacuole form-
ation (Macomber & Sprinz, 1967; Warhurst & Hockley, 1967); during 
vacuolation autolysis occurs inside the cytosome that is formed on ex-
posure to chioroquine which leads to the cytoplasmic destruction of para-
sites as a result of leakage of enzymes (Warhurst & Williamson, 1970). 
Protein synthesis, as well as RNA synthesis, is essential for the 
stimulation of clumping and vacuolation (Homewood et al., 1971; 
Warhurst & Robinson, 1971; 	Warhurst et al. , 
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1971; Warhurst & Baggaley, 1972; 	Warhurst et al., 1972,1974). This 
process is therefore, inhibited by high concentrations of chloroquine. 
Two explanations have been suggested to account for the way 
chioroquine acts to bring about sequestration within vacuoles and 
cytoplasmic destruction. Homewood etal. (1972a,b)suggest that the 
drug may act by inhibiting haemoglobin digestion in plasmodia. 	The 
lysosome 
theory given is that the pH of the / , which is usually maintained 
at an acidic level is raised by the consumption of hydrogen ions during 
protonation of chioroquine. 	In P, berghei pigment clumping can be 	in- 
duced by raising the pH without ch].oroquine (Homewood et al., 1972c). 
An alternative explanation is based on the observation that chloroquine 
is found to - be concentrated in lysosornes of mammalian cells (Allison & 
Young, 1964; Fedorko et al., 1968) which can be considered to be ana- 
logous to the digestive vacuole of the parasites. 	This concentration 
could be a function of lysosomal activity due to the direct inhibition 
dependent 
of proteolytic enzymes (De Duve et al.,, 1974) and is energy/(Polet, 1970). 
In examining chloroquine-induced pigment clumping and vacuolation, 
Warhurst (1973) postulated clumping sites, where at low concentrations 
of chloroquine, the drug is associated. 	It was suggested that the 
clumping receptors were not lost from chloroquine-resistant parasites 
but were present in a modified form which was still accessible to suit-
able drugs; these sites may be localized in the digestive vacuole 
membrane (Warhurst & Thomas, 1975a). 	Using electron microscopy 
3
-H- 
chloroquine was found to be localized in pigment containing digestive 
vacuoles of P. berghei (Aikawa, 1972). 	Another antimalarial drug, 
mepacrine, was also found to be localized at the host-parasite inter- 
face and on the membrane of digestive vacuoles (Warhurst & Thomas, 1975b). 
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Chloroquine is concentrated in parasitized cells to a greater ex-
tent than in uninfected red blood cells (Macomber et a].., 1966; Polet 
& Barr, 1969; Fitch, 1969, 1970). 	It has been suggested that the 
parasites require energy for accumulation of the drug (Fitch et a].., 
1974b,c,1975a) ; Plasmodia infected cells use higher quantities of glu- 
cose than uninfected cells (Moinen, 1979). 	Fitch attributed such 
accumulation to the existence of binding sites in the parasites. 
These 'binding sites' should not be confused with 'clumping sites' which 
are thought to be separate sites as the affinities of amino-alcohol 
antimala.rials for the two sites differ (Warhurst & Thomas, 1975a). 
Three classes of binding sites were proposed based on their association 
constants (Fitch, 1969). Fitch foundthat chioroquine_resistant par aSite1 
boundless dn sensitive forms_(Fitch, l969;Fitchet,1974c, 19 ru 
Kramer & Matusik (1971) suggested that one class of binding sites 
(high affinity) were associated with the parasite membranes whereas 
another class (low affinity) were freely soluble. 
Fitch et al. (1974a, 1975a,b,1978) have suggested that the high affinity 
receptor may be present in the erythrocyte membrane of infected cells 
rather than in the parasites themselves. 	The authors propose that the 
parasites modify the erythrocyte surface to alter constituents which 
normally prevent chloroquine accumulation and that resistance to the 
drug arises by the way parasites modify the erythrocyte surface. 
There is evidence that P. berghei selectively degrades certain proteins 
in the erythrocyte membrane (Weidekamm et al., 1973); parasites also 
modify the red blood cell surface causing indentations and surface 
protrusions with P. berghei (Bodammer & Bahr, 1973) and with P. falciparum 
(Balcerzak et al., 1972). 
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A different theory for the mechanism of chloroquine-resistance 
was suggested by Howells (1970), who proposed a change to aerobic 
metabolism in the respiratory mechanism of chloroquine- resistant P. 
berghei. 	This theory has since been refuted due to technical dif- 
ficulties in the method used for detecting functional mitochondria and 
because of host cell contamination (Howells & Maxwell, 1973a,b) 
The exact mode of action of chloroquine, therefore, still remains 
unclear and the mechanisms proposed for chioroquine-resistance are 
still mainly speculative. 	However, from the work carried out so far, 
there is strong evidence that chloroquine-resistance may be a function 
of uptake. 	The clumping sites (Warhurst, 1973) and binding sites 
(Fitch, 1969) are likely candidates for such a mechanism. 
1.7 Mefloquine - Mode of Action 
The emergence of chloroquine-resi stance in P. falciparum resulted 
in an intense search for new drugs. 	One of the most promising drugs 
to emerge from the antimalarial screening of drugs by the United States 
army in the 1960s is inefloquine. 	This drug is now undergoing clinical 
trials on its own (Canfield et al., 1973; Rieckmann et al., 1974; 
Trenholme et al., 1975; Hall 	.., 1975 c Clyde et al., 1976b; 
Hall, 1976; Schmidt et al., 1978) and in combination with other drugs 
(Hall et al., 1977; Doberstyn et al., 1979). 	Mefloquine is a clinic- 
ally useful quinolinemethanol with antimalarial activity. 	In addition, 
it has been shown to have prophylactic activity against drug resistant 
P. falciparum and might have a long term suppressive activity against 
asexual forms (Rieckmann et al., 1974; Clyde et al. , 1976b). Clinical 
studies have shown that mefloquine persists for a relatively long time 
in man (Trenholine et al., 1975) . 	However, there is no evidence of 
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activity against secondary tissue schizonts of P. vlvax (Trenholme 
et al., 1975; Clyde et al., 1976b) and of P. cynoinolgi (Schmidt et al., 
1978). 	How mefloquine is stored and metabolized is yet to be determined. 
Mefloquine does not bind significantly to DNA (Davidson et al., 
1975; Peters et al., 1977a). This is the first report of an active 
compound in the quinoline- acri dine class of antimalarials which does 
not strongly bind to DNA by intercalation. 
Fitch and his co-workers have investigated the process of mefloquine 
accumulation using chloroquine-resistant and sensitive strains of P. 
berghei (Fitch etal., 1979). 	They confirm the earlier finding of 
Peters et al. (1977a) that chioroquine and mefloquine competitively in- 
hibit their respective accumulation. 	Using P. berghei, Peters et al. 
(1977a) observed that mefloquine competitively inhibits pigment clumping 
which is induced by ch].oroquine, although mefloquine. itself did not 
cause clumping. 	Fitch et al. (1979) found that more than half as much 
mefloquine was accumulated by uninfected erythrocytes as infected 
erythrocytes. 	Furthermore, mefloquine was accumulated more effectively 
than chloroquine by uninfected red blood cells and by cells infected 
with chloroquine-resistant P. berghei. 	Unlike chloroquine, they found 
that the process of niefloquine accumulation was not stimulated by glu- 
cose (substrate). 	In view of this, it was proposed that the two drugs 
shared a common group of receptors and were accumulated by the same 
process; for some unknown reason mefloquine may have a greater access 
to the receptors than chloroquine. 	The undiminished accumulation of 
mefloquine with chloroquine-resistant P berghei infected cells provides 
an, explanation for the activity of this drug in treating ôhloroquine-
resistant malaria. 
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Toxicity tests and the study of the effect of mefloquine on the 
immune response in mice are being undertaken (Thong et al., 1979). 
These authors have found that human lymphocytes were more resistant to 
the drug than mouse lymphocytes. 	Nevertheless, the response to mito- 
gens were equally depressed. 	Therefore clearly, extrapolations from 
mice to humans must be viewed with caution. 
As mefloquine is a relatively new drug, so far there is no evidence 
of stable resistance to it. A report of unstable mefloquine-resistance 
in P. berghei has appeared (Peters et al., 1977b). 
1.8 	Genetics 
Genetic work on malaria parasites has, until recently, been diffi-
cult due to the complex life cycle of the parasite, involving two hosts. 
The different stages of the parasite suggest variation in gene expression. 
In addition to drug resistance genetic studies would be of value to 
various questions concerning taxonomy. 	A more general application 
would be to confirm that malaria parasites undergo a eukaryotic life 
cycle, with sexual stages, rather than a prokaryotic process of genetic 
exchange. Haploid clones produce both male and female gametocytes 
which give rise to gametes which can either self or cross fertilize 
with gametes of different clones. 	It is hoped that such studies would 
lead to a precise location of meiotic reduction division (Walliker et 
al., 1975) which is thought to occur during oocyst development (Sinden 
& Canning, 1973). 
1.8.1 	Cytogenetics 
The unusual pattern of chromosomal organization in malaria parasites, 
namely the absence of condensation throughout the division of vegetative 
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stages precludes the estimation of chromosome numbers by light micro-
scopy (Wolcott, 1954, 1957; Canning & Anwar, 1968). In the absence 
of condensed chromosomes, Sinden (1978) proposes three methods which 
can be used to determine chromosome numbers. These are: 
To calculate the number of linkage groups by genetic analyses 
- there are few known markers in Plasmodia to make this type of 
analyses feasible in the near future. 
To count the number of kinetochores, each of which is attached 
to a diffuse chromosome. 
To count the number of kinetochore microtubules in serial 
sections of spindles. 
The limited cytological data suggests a haploid number of 8 - 10 
chromosomes (Schreve1 eta].., 1977) in murine Plasmodia. 	Recent studies 
by Sinden and Strong (1978) estimate the chromosome number as fourteen 
in the haploid genome of P. falciparum. 	As both micro-and macrogameto- 
cytes can arise from cloned haploid blood forms, conclusions about sex 
chromosomes are not possible; the lack of condensed chromosomes prevents 
positive identification of chromosomes. 
Both mitosis and meiosis are thought to occur in malaria parasites. 
The parasites undergo mitosis during erythro-and exoerythrocytic 
schizogony, sporogony and microgametogenesis. 
There is an absence of condensed chromatin except during telophase 
of the final microgametic division (Sinden 1978). 	Canning and 
Morgan (1975) suggest that meiosis is a division with no chiasmata bet-
ween chromosomes. 	The location of meiosis remains unknown as a result 
of the inability to count chromosomes. 	None the less, the limited data 
available suggests that the number of kinetochores is constant throughout 
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the life cycle and that meiosis takes place in the zygote. 	If 
zygotic division were mitotic 2n kinetochores would be expected; how-
ever, the observed number of kinetochores found is n. 
Therefore, the location of genes awaits further studies. 	This 
information could eventually come from molecular biologists; studies 
will probably soon be in progress to clone the Plasmodium genome.. 
1.8.2 	Hybridization Between Strains 
Investigations have mainly been restricted to laboratory animal 
species. Aotus monkeys in which human inalarias can grow are costly 
and thus cannot be used for genetic work because of the large number 
of animals that would be required. 	The recent development of in vitro 
culture systems may enable genetic studies to be carried out with human 
malarias. 	The first genetic studies with Plasmodia were by Greenberg 
and Trembley (1954a,b; Trembley & Greenberg, 1954; Greenberg, 1956). 
Using the avian parasite P. gallinaceum, they crossed two lines which 
differed in their resistance to pyrimethamine and their ability to pro- 
duce erythrocytic and secondary exoerythrocytic forms. 	A cross was 
conducted by allowing mosquitoes to feed on blood containing a mixture 
of gametocytes of the two different lines. 	They detected non parental 
parasites which indicated that recombination between the characters dis- 
tinguishing the parent lines had taken place. 	Unfortunately, this 
interpretation was open to question as one of the markers (production 
of secondary exoerythrocytic forms) was known to be unstable (Trembley 
et al., 1951). 	Furthermore, their parent lines were uncloned which 
adds doubt to the validity of their results. 
Rodent malaria parasites have proved to be especially suitable 





proved to be genetically diverse (Bealeet al. , 1978). 	In addition, 
mice, in which the parasites can grow are available in large numbers. 
Like P. gallinaceuin, all stages of the life cycle can be maintained in 
the laboratory. Genetic recombination in rodent malaria parasites has 
been demonstrated by Wallikeretal. (1971, 1973, 1975, 1976); Morgan 
(1974); Rosario (1976a,b); Oxbrow (1973) and MacLeod (1977) in this 
laboratory. These studies illustrate Mendelian inheritance of enzyme, 
drug resistance, antigenic and virulence markers. 	That the rodent 
species of malaria were polymorphic for several enzyme markers was an 
invaluable discovery which was developed by Carter (1970, 1973) and 
Carter and Walliker (1975). 	In these studies, two lines of P. yoelii 
which differed in their pyrimethamine response and had variants for 
the enzyme glucose phosphate isomerase (I) were shown to cross- 
fertilize resulting in recombinant markers (Walliker et al., 1971, 1973). 
A similar cross was conducted with another species,P. chabaudi, which 
was polymorphic for the enzymes 6-phospho gluconate dehydrogenase (6PGD) 
and lactate dehydrogenase (LDH) as well as having differences in pyri-
methamine response. 	The results also confirmed the haploidy of the 
blood forms (Walliker et al., 1975). 	Genetic analyses with pyri- 
inethamine-resistance in P. yoelii were conducted by Morgan (1974), with 
chloroquiñe-resistance in P. chabaudi by Rosario (1976a,b) and by MacLeod 
(1977) with pyrimethamine- and sulphadiazine-resistance in P. chabaudi. 
Wal].jker etal. (1976) also demonstrated that variations in virulence 
were due to genetic differences by crossing two lines of P. yoelii which 
differed in the enzyme forms of GPI, their pyrimetha.mine resistance and 
in their growth'pattern (virulent or mild). 	Oxbrow (1973) investigated 
the genetic basis of cross-protection differences between subspecies of 
P. yoelii and found that the ability of parasites to grow in immunized 
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mice was controlled by genetic factors which recombine with other 
markers. 
Yoelietal., (1969) reported a different gene transfer mechanism 
between malaria parasites. 	They suggested that genetic exchange 
could take place between trophozoites of two parasite lines during 
their simultaneous development in the same red blood cell. 	They 
called this process synpholia. 	Two lines were used, a pyrimethamine- 
resistant P. vinckei line which was not infective to hamsters and a 
pyrimethamine-sensitive P.; berghei line which was infective to hamsters. 
Both lines were mixed together and inoculated into mice; then the mix- 
ture was injected into pyrimethamine treated hamsters. 	In 6 out of 
12 of these hamsters pyrimethaznine-resistant P. berghei was detected. 
No confirmation of this process has been reported in subsequent work 
done in this laboratory or in other laboratories (for example 
Schoenfield et al., 1974). 	The results presented in this investigation 
are also inconsistent with synpholia as a mechanism for genetic exchange 
(see Sections 4.4 & 4.5). 	The most likely explanation for the results 
of Yoeli et al. (1969) is that the pyrimethamine treatment used in the 
drug tests had selected for a mutation to pyrimethamine-resistance in 
P. berghei, as the dose used would have been sufficient to select for 
such a change (Diggens et al. , 1970). 
1.9 	Aims of this Investigation 
The present study uses a genetic approach to investigate the basis 
of chloroquine- and mefloquine-resistance in the rodent malaria species 
P. chabaudi. This species provides a good model for genetic analyses 
due to the considerable amount of enzyme polymorphisms found among wild 
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isolates (Carter & Walliker, 1975). 	The aims of this study are as 
follows: 
(1) Until recently, no genetic work on chloroquine-resistance has 
been carried out. 	Rosario (1976a,b) developed a line resistant 
to a low level of the drug(3mg kg- 
1 
 for 6 days) using a gradual 
increase of drug pressure over a number of passages. 	This 
line was shown to be stable and the resistance character demon- 
strated a Mendelian mode of inheritance. 	This present invest- 
igation involved selecting for a high level of chloroquine-
resistance in order to determine: 
whether a high level of resistance was due to mutation 
events, and 
if so, how many mutations were involved. 
Such mutations could be at either the same locus or at several 
loci. 	The results are discussed in relation to these two 
possibilities. 
(2) Previous studies indicated that parasites resistant to chioro- 
quine at a low level were at a selective advantage (Rosario, 
1976b; Rosario et al., 1978). 	In this work, competition ex- 
periments are carried out with the highly chloroquine-resistant 
line developed. 	This subject is important in considering how 
drug resistant parasites are disseminated in the parasite 
population. 
(3) Studies have been carried out on mefloquine to determine how 
easily, if at all, resistance to this drug can be obtained. In 
this study resistance to inefloquine was developed and the stab-
ility of this character was investigated. 
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2. MATE RI MS AND METHODS 
2.1 	Lines of P. chabaudi 
2.1.1 	Origins 
P. chabaudi was first discovered in the Central African Republic 
in the thicket rat (Thamnomys rutilans) (Landau, 1965). 	The life cycle 
and basic biology of the parasite were described in detail by Landau and 
Landau and 
Killick-Kendrick (1966) ,Wery (1968) ,Landau et al. (1970) and /Boulard (1978). 
The parasite was reduced to the rank of a subspecies (P. vinckei 
chabaudi) by Bafort (1968). 	Further studies on the morphology and 
enzyme patterns of the parasite has lead to its present specific name, 
P. chabaudi (Carter & Walliker, 1975). 
2.1.2 	Life cycle 
P. chabaudi has a typical malarial life cycle (see Section 1.2). 
In the liver cells, the schizonts of this species mature in 52 - 53 
hours. 	In the blood, the parasites undergo schizogony approximately 
every 24 hours producing schizonts of 4 - 8 merozoites. 	During the 
early stages of infection with P. chabaudi, the development of the 
parasite in the blood is synchronous. 	Unlike other species. where 
parasites at varying stages of development can be seen, P. chahaudi 
matures synchronously; after schizogony, for example, ring forms are 
predominantly seen in the peripheral blood. 	A typical course of in- 
fection of P. chabaudi is illustrated in Figure 2. 	The sexual forms 
are predominantly found after the peak of infection. 
2,1.3 	Definition of Terms 
The terms isolate, line, clone and stabilate, which are used 
throughout the text are defined as follows: 
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Isolate - This is a sample of parasites collected on a unique 
occasion from a wild rodent or mosquito and preserved either by passage 
in laboratory animals or as deep-frozen material. 	An isolate is not 
necessarily genetically homogeneous and may contain mixtures of more 
than one distinct species,, 
Line - This is a group of parasites which has undergone a particular 
laboratory passage. 	A "line" of parasites needs not necessarily be 
genetically identical. 	By definition every laboratory manipulation 
of parasites results in a new "line". 	In this investigation, parasites 
are classified as belonging to a new "line" only after a special treat-
ment such as selection for drug resistance. 
Clone - A "clone" is an infection derived from a single parasite 
by asexual reproduction. 	All parasites obtained from a single clone 
are assumed to be genetically similar. 
Stabilate - This refers to a collection of parasites preserved on 
a unique occasion. 	Liquid nitrogen preservation is the usual technique 
employed. 
2.1.4 Parasite Lines 
The parasite lines used in this investigation are shown in Table 1. 
The original drug sensitive line of AS and AJ were obtained from 
separate thicket rats. 	These lines were cloned and were characterized 
for two enzymes by starch gel electrophoresis; they were observed to 
be polymorphic for lactate dehydrogenase (LIE) and 6-phosphogluconate 
dehydrogenase (6PGD). 	The AS(OCQ)  line was derived from the AS(Sens) 
line as were all the other AS lines. 	This line was sensitive to 
chloroquine and resistant to pyrimethamine. Pyrimethamine resistance 
was established in a single step using a high pressure method (MacLeod, 
TABLE 1. 	Parasite Lines of P. chabaudi 
Line Enzyme Types 
LDH 	6PGD 
Drug P.esponse 
PYR CQ MF 
(Pyrirnethamine) (Chioroquine) (Mefloquine) 
AJ(Sens) 2 	3 S S S 
AS (Sens) 3 	2 S S S 
AS(OCQ) 3 	2 P S S 
AS (3CQ) 3 	2 P. R(3) S 
AS (15CQ) 3 	2 R R(15) S 
AS (200) 3 	2 P R(20) S 
AS (30CQ) 3 	2 P R(30) S 
AS (12MT) 3 	2 P. R(?) R(12) 
AS 	(15MP) 3 	2 P R(?) P(15) 
AS (30MF) 3 	2 R RM R(30) 
-1 PYP-S 	Sensitive to 15 mg kg pyrimethamine for 4 days. 
PYP-R : Resistant to 15 mg kg- 
1 
 pyrimethamine for 4 days. 
-1 cx-s : Sensitive to 3 mg kg 	chioroquine for 6 days. 
Resistant to dose of chioroquine indicated in brackets for 
6 days (see Table 4) 
MF-S : Sensitive to 10 mg kg- 
1 
 mefloquine for4 clays. 
MF-R : Resistant to the doses of mefloquine indicated in brackets 
for 4 days. 
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1977). 	The AS (30) line was derived from the AS (OCQ) line by 
Rosario (1976a,b). 	This line was cloned and was subsequently used 
for selection in this present study. 	The selection of the other 
lines are described elsewhere (see Sections 2,8 & 2.9). 
2.2 Maintenance of Parasites in the Laboratory 
2.2.1 	Mammalian Host 
The mammalian hosts used were mice and white rats. The mice 
(Mus musculus) were predominantly inbred 4-6 week old C57 black mice 
from the Centre for Laboratory Animals, Edinburgh. 	Mixed strains of 
mice from the mouse house in the Department of Genetics, Edinburgh, 
were occasionally used for routine blood passage and cloning. 	White 
rats (Rattus norvegicus) were used for concentrating gametocytes 
(MacLeod & Brown, 1976); these were supplied by the Centre for 
Laboratory Animals, Edinburgh. 	All rodents were kept in polypropylene 
cages with sawdust as bedding, fed with animal cake (MacGregor's of 
Leith) and were given drinking water ad lib supplemented with 0.05% 
PABA (para-aminobenzoic acid), an essential parasite growth requirement 
(Hawking, 1953; Peters, 1970). 	The animal room was maintained at 
18 - 22 °C under natural light conditions. 
2.2.2. Blood passage of Parasites 
For blood passage, parasitized red blood cells were taken from 
infected rodents and diluted in either cold citrate saline (0.9% NaCl, 
1.5% Na Citrate) or in cold heparinized serum Ringer (50% calf serum 
& 50% mammalian Ringer). 	The diluted blood was then injected into 
uninfected animals either by intravenous or intraperitoneal routes. 
The day of inoculation was called Day 0 (D 0) and subsequent days Day 1 
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Day 2 (D2), etc. 	Infection levels were monitored by examining 
thin blood films made from the tail and stained with Giemsa's stain... 
(B.D.H. Chemicals Ltd.) at pH 7.2. 
2.2.3 Mosquito Transmission 
The invertebrate host used for cyclical transmissions was 
Anopheles stephensi. The mosquitoes were kept at a temperature of 
about 25°C and 90% humidity. 	They were subjected to a 12 hour light/ 
dark cycle, and fed with a 10% solution of glucose in a 0.05% solution 
of PABA in water. 
Transmissions of the parasite were based on methods described by 
Landau and Killick-Kendrick (1966). 	Infected rodents in which mature 
gametocytes were present were exposed to mosquitoes which had been 
previously starved for 24 - 48 hours. 	The mosquitoes were allowed to 
feed on the rodents for about 1 - 3 hours. 	Seven days later, mos- 
quitoes were dissected to check for oocysts. 	On days 15 and 17 after. 
the initial blood meal, the mosquitoes, which were presumed to contain 
sporozoites in their salivary glands, were allowed to feed on an tin- 
infected mouse, thus transmitting an infection. 	Parasites could be 
detected in the blood 	4 - 8 days after the mosquito feed. 
2.2.4 Liquid Nitrogen Preservation 
Parasites were stored in liquid nitrogen using the method described 
by Lumsden et al. (1966). 	Before freezing, parasitized blood was mixed 
with a balanced solution of inorganic salts buffered at pH 8.0 with 
phosphate buffer in the proportion of 9 parts blood to 1 part salts 
solution. 	Glycerol was added to give a final concentration of 7.5%. 
The mixture was then dispensed into capillaries, sealed and plunged 
into liquid nitrogen to be stored until required. 	Parasites were 
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removed from storage by transferring a capillary from nitrogen into 
water at room temperature. 	The capillary was then opened, the con- 
tents diluted and injected intraperitoneally into a mouse. 	Infections 
became patent 7 - 14 days after inoculation. 
2.3 Parasitaemia Estimations 
The percentage parasitaemia was determined by counting the number 
of parasitized red blood cells in Giemsa-stained smears. A total of 
2,000 red blood cells was counted if the infection was high (>5%) and 
in a total of 4,000 red blood cells if the infection was low (<5%). 
No, parasitized RBCs 
% Parasitaemia = 	 x 100 
Total no. RBCs 
Standard Error (S.E.) estimates were calculated according to the 
formulae shown on Table 34 (in Appendix). 
2.4. Preparation of Standard Inocula 
2.4.1 	Inocula Containing 106  Parasites 
A donor rodent was either bled from the tail or sacrificed and 
bled from the brachial vessels. 	The blood was diluted with serum! 
Ringer so that 0.1 ml contained 
10  
parasites. 	The diluted blood was 
kept cold until required. 	Mice were then inoculated with 0,1 ml ali- 
quots of the diluted blood. 
2.4.2 	Inocula Containing 0.5 Parasite for Cloning 
Clones of blood forms were obtained by a dilution technique 
(Walliker, 1976). 	The donor animals used for cloning were those with 
rising infections, to ensure that the infected cells were infected by 
only a single parasite. 	Dilutions were made until a concentration of 
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0.5 parasite per 0.1 ml of inoculum was obtained. 	0.1 ml aliquots of 
the diluted blood were then injected by the intraperitoneal route into 
a large number of mice (50 - 100). From the proportion of mice which 
become infected, the numbers established from one, two or more parasites 
could be estimated by means of the Poisson distribution. For example, 
by inoculating 0.5 parasite per mouse, approximately 407o of the animals 
injected should become infected. Of these 75% are predicted to be 
clones. 	Although these calculations are only approximate, they are 
adequate for the purpose of this work; with several markers, mixtures 
of clones can readily be detected. 	This technique is based on the 
assumption that a single parasite is capable of establishing an infection; 
this was originally demonstrated by Diggens (1970) using a dilution 
method. 
2.5 	Starch Gel Electrophoresis 
Enzyme characterization of the blood forms of the parasite was 
undertaken using starch gel electrophoresis following the technique des-
cribed by Carter (1973, 1978). 	The material was prepared for electro- 
phoresis as described by Carter (1978), the parasites being lysed with 
saponin and freeze-dried until required. 	Variants of lactate dehydro- 
genase (L]}!) and 6-phosphogluconate dehydrogenase (6PGD) were examined 
using the enzyme assay solutions outlined by Carter (1973, 1978). The 
gel buffer used for LLI was 0.065M Tris-0.222M citrate, pH 6.5 and the 
Citrate 
electrode buffer was 0.22M Tris-0.0785M4 pH 6,2. 	The gel buffer used 
for 6PGD was modified; O.OlM phosphate buffer, pH 7, with the addition 
of NAEP was used (0.02 mg/ml). The electrode buffer was 0.11.1 phosphate 
pH 7; this was also modified by adding 10 mg NADP to the cathodal 
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trough. 	The gel was run for 17 hours instead of 4 hours used by 
Carter (1973, 1978). 	All reagents were obtained from Sigma Chemical 
Company. The voltage gradient used was 3V/cm (42 volts and 24 mA) 
2.6 Source, Preparation and Administration of Drugs 
All drug doses were expressed as mg kg- 1 body weight. 	The drugs 
were administered orally. When not in use, all of the drug solutions 
were keptcold. 
2.6.1 	Chioroquine (CQ) 
Chloroquine sulphate (commercially known as Nivaquine) was obtained 
from May & Baker Ltd., England, in the form of a solution (40 mg CQ base 
per ml) . This solution was diluted with distilled water to obtain the 
concentrations required. 	The drug was diluted so that for mice 
weighing lOg, 0.1 ml of the drug solution contained the dose of chloro- 
quine required. 	The mice were individually weighed so that exact 
amounts of the drug were given to each animal. 
2.6.2 Pyrimethamine (PYR) 
Pyrimethainine (commercially known as Daraprim) was supplied by 
the Wellcome Research Laboratories, England, in the form of a powdered 
base. 	The drug dose was related to the mean weight of the group of 
mice used for the test. 	Dilutions were made so that a specific dose 
of the drug could be administered in 0.1 ml of the solution. 	Because 
pyrimethamjne is insoluble in water, the powder was dissolved in a 
small quantity of warmed lactic acid. 	The solution was then diluted 
with distilled water to the required concentration, 
30. 
2.6.3 	Mefloquine (IT) 
Mefloquine (WR 142, 490) was supplied by the Walter Reed U.S, Army  
Institute of Research in the form of a powder of the hydrochloride salt. 
As it was insoluble in water, the drug was dissolved in a small quantity 
of warmed DMSO (dimethyl sulphoxide). 	The solution was then diluted 
with distilled water to obtain the required concentration. 
2,6.4 	Mepacrine (MP) 
Mepacrine (quinacrine dihydrochloride) was obtained from Sigma 
Chemical Company in the form of a powder. It was dissolved in dis-
tilled water to the concentration required. 
2.6.5 	Quinine (ON) 
Quinine (quinine dihydrochloride) was obtained from B.D.H. 
Chemicals Ltd., in the form of a powder. 	The drug was dissolved in 
distilled water. 
2.7 Standard Drug Tests 
All of the drug tests involved inoculating intraperiton- 
eally a group of five or seven female C57 black mice each with 106 
blood forms of the parasite line under investigation. 	The mice were 
standardized for age (4 - 5 weeks old) and were approximately the same 
weight (15 - 20g). 	Three hours after inoculation the first dose of 
the drug was administered; two mice were left undrugged as controls. 
The drug was then administered at the same time each day thereafter. 
Blood smears were taken from the tail of each mouse on appropriate 
days after completion of drug treatment and examined for parasites. 
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2.7.1 Chloroguine 
Several tests were conducted to evaluate the most effective 
drug test. 	 4-day and 6-day tests were compared. 	In these 
tests the drug was administered for the appropriate number of days 
and infections monitored on specific days after treatment was com-
pleted. 
The infectivity of the parasites during drug treatment was 
determined. 	The AJ(Sens) and AS(3CQ) lines were compared. 	106 
parasites were inoculated into each of a group of mice. 	2 mice of 
each line were left undrugged (UND) and the other mice were drugged 
-1 	 -1 
(DG) with either 5 mg kg or 10 mg kg chloroquine daily for 6 days. 
After the initial inoculation, subinoculations into clean mice were 
carried out on specific days. 	Thereafter, blood smears were taken 
to monitor any resulting infections, 
"Drug delay" tests were carried out in which a group of mice were 
inoculated each with 
10  
parasites. On Day 3, when the parasitaemia 
was about 1% drug treatment was started. The parasite response was 
monitored daily. 	Drug treatment was continued to determine whether 
there were any differences between parasite lines. 	The parasitaemias 
of the different parasite lines were compared. 
2.7,2 Pvrimethamine 
A four-day test was used to distinguish between pyrimethamine-
resistant (PYR-R) and sensitive (PYR-S) blood forms of the parasite. 
15 mg kg -1 pyrimethamine was administered daily for four days. Thin 
blood smears were examined on days 6 and 8; the parasitaemias were 
calculated. The parasites which survived the treatment were classi-
field as resistant and those which failed to survive, as sensitive. 
Fig.3 Development of a High Level Chioroquine-Resistance 
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2.7.3 	Mefloquine 
A 1 4-day' suppressive test was used to distinguish between the 
lines. 	The appropriate dose was used (7, 10, 15 & 30 mg kg 1). 
Parasites which survived the treatment were classified as resistant 
and those which failed to survive as sensitive. 
2.7.4 	Mepacrine 
Drug tests similar to those of mefloquine were conducted. Doses 
of 13 and 15 mg kg inepacrine were used. 
2.7.5 	Quinine 
Drug tests similar to those of mefloquine were conducted with 
the exception of the drug dose used. 	Much higher doses of 150, 200 
and 250 mg kg- 
1 
 were required. 
2.8 Chioroquine-resistance 
2.8.1 Selection of a High Level of hloroauine-Resistance 
A continuous low pressure method was used to increase the level 
of resistance. 	Starting from a line already resistant to 3 mg kg' 
chloroquine (AS3CQ)(Rosario, 1976a,b), a group of mice were each in- 
jected with 106  parasites and treated daily with chloroquine. 	The 
parasites which survived the treatment were then taken and 106  para- 
sites were injected into each of a further group of mice. 	These mice 
were in turn treated with a slightly higher dose of chloroquine. 
This procedure was continued, the doses used for selection being 
shown in Figure 3. 	The dose and duration of drug treatment was 
chosen according to the parasite response. 	If the parasites were 
- 	increasing in number during selection, the dose was increased. 	At 
3. 
various stages of the selection procedure the parasites were trans-
mitted through mosquitoes in order to investigate the stability of 
the resistance on mosquito transmission. 	The parental AS(3CQ) line 
was used as a control and the parasites were tested at the same time 
as the parasites undergoing selection, to determine whether any sign-
ificant changes of resistance had occurred. 
2.8.2 Tests for Different Levels of Chioroquine-Resistance 
At various stages of selection the parasites were transmitted 
through mosquitoes to test for the stability of the resistance (Fig. 
3). 	These included parasites which had survived 15, 20 and 30 mg kg- 1 
of the drug; these lines were denoted as AS (15CQ), AS (20CQ) and 
AS (30CQ) respectively. 	Comparative tests were devised to determine 
whether these lines differed from each other and could therefore be 
classified as demonstrating different levels of resistance. 	Each line 
was tested using a range of doses from 5 - 30 mg kg- 
1 
 chloroquine. 
In addition the parasites were tested for stability on multiple blood 
passage without drug pressure. 	The different lines were also tested 
for their response to mefloquine, mepacrine and quinine. 	The para- 
sites were classified according to the rate at which they produced 
patent parasitaemias after drug treatment. 	The most important factor 
in these drug tests was the day in which the parasites could be de-
tected in the blood. 
2.8.3 	In vitro Drug Tests 
Short term in vitro drug tests, according to the micro-technique 
described by Rieckniann et al. (1978) for P. falciparum, were under-
taken to determine whether this method could be used to differentiate 
between chloroquine-resistant and chloroquine-sensitive lines of P 
Fig.4 Method for a Genetic Cross 
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chabaudi. 
Two lines of P. chabaudi were tested:- 
AJ(Sens) 
AS (300Q) 
Because P. chabaudi undergoes synchronous development in the blood, 
with schizogony occurring around midnight, cultures were set up in 
the morning when the parasites were at an early trophozoite stage. 
They were incubated for various periods up to 24 hours in wells of 
micro-titre plates. Each well contained: 
50 p1 RPMI 1640 medium, supplemented with Hepes buffer 
and sodium bicarbonate. 
5 p1 parasitized blood from donor mice. 
Various doses of chloroquine diluted in RPMI 1640 medium. 
Cultures were maintained in a candle jar at 37°C, After incubation, 
thin blood smears were taken from each well and examined for parasite 
maturation. The development of the parasites was also monitored in 
vivo by taking thin blood films of the donor mice. 	This was done 
in order to determine when the cultures should be examined. 
2.8.4 	Genetic Studies 
(a) Conducting a Cross 
The strategy used for making crosses in this investigation is 
illustrated in Figure 4, 	This is a modified method to that described 
by Walliker et al. (1975). 	Each parent line was first injected 
separately into splenectomized rats; splenectomized rats were used 
to enhance gametocyte production (MacLeod & Brown, 1976; MacLeod, 
1977). 	Splenectomy was carried out at least 48 hours before inocu- 
lation of parasites by the intravenous route. 	Four days later, when 
Fig.5 Schematic Diagram of a Cross 
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a large number of mature gametocytes were present and exflagellation 
of the microgametes was observed, the rats were sacrificed and the 
blood of each parent line mixed. 	The blood mixture was then placed 
in a membrane feeding apparatus (Rutledge et al., 1964) . 	Minimal 
heparin (5 units per ml) was used to prevent clotting. 	Mosquitoes 
were then allowed to feed on the blood mixture. 	After 15 days the 
mosquitoes were permitted to feed on further animals to transmit in- 
fections. 	Control studies on each parent line were conducted in 
parallel. 	After mosquito transmission stabilates of infected blood 
were prepared and stored in liquid nitrogen and used for subsequent 
analyses. 
During mosquito transmissions, midguts were examined (on D 7) 
to determine whether one parent line had produced more oocysts than 
the other line used for the cross. 	This was to give an indication 
whether each line had produced similar numbers of gametocytes and 
hence whether equal numbers of each line were present in the cross. 
Assuming Mendelian inheritance, a schematic diagram can be drawn 
to illustrate what may happen during a cross (Fig. 5). 	Assuming 
random fertilization of gametes, the two lines differing in two un-
linked markers A and B, for example, should produce progeny in the 
ratios shown. 	Reassortment of genetic markers takes place at meiosis; 
meiosis is thought to occur some time between zygote formation and the 
emergence of the blood forms. 
(b) Analyses of the Products of a Cross 
(i) Tests on Uncloned Products 
The uncloned products of crosses between drug resistant and 
sensitive lines differing in enzyme forms, were examined for their 
enzyme types after treatment with pyrimethainine and chloroquine, 
Figure 6: Reconstruction Experiments 
Experiment No. %AS %AJ 
1 100 0 
2 90 10 
3 80 20 
4 70 30 
5 60 40 
6 50 50 
7 40 60 
8 30 70 
9 20 80 
10 10 90 
11 0 100 
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This gave an indication of whether or not cross-fertilization had 
taken place. 	If the parental lines were transmitted without cross- 
fertilization only the enzyme types of the drug resistant parents 
would have been observed after drug treatment. 	The presence of the 
sensitive parental enzyme types after drug treatment, showed that 
cross-fertilization had occurred between the two lines. 
(ii) Cloning and Characterization 
Clones were obtained from the products of the cross and from the 
parental controls by dilution. 	Each clone was analysed for parental 
characters. In some experiments, the uncloned progeny were treated 
with chloroquine at a specific dose for 5 or 6 days before cloning. 
The clones obtained in these experiments had thus been pre-selected 
for resistance to chloroquine at the level given. 
2.8.5 Reconstruction and Competition Experiments 
(a) 'Reconstruction 
Reconstruction experiments were carried out in which deliberate 
mixtures of parasites with AS and AJ enzyme types were made in various 
proportions in order to establish at what level the electrophoresis 
system could detect quantitative differences. 	The lines used were 
AS(3OCQ) and AJ(Sens) (See Table 1). 	In these experiments 106  para- 
sites of each of the two lines were each injected into groups of 10 
mice. 	When the infections were high (about 40%) the animals were 
sacrificed and the parasitized blood of each line was pooled separately. 
The pooled parasitaemias of each line were measured from thin blood 
films. Estimates of pooled red blood cell counts were made using a 
Coulter counter. 	The parasites were then mixed so that each mixture 
contained each line in the proportion shown on Figure 6, 	The parasites 
Figure 7: Competition Experiments 
50:50 Mixtures of Blood Forms of Different Lines 
Experiment 1 AS (Sens) Vs 	AJ (Sens) 
Experiment 2 AS (30CQ) Vs 	AS (OCQ) 
Experiment 3 AS (30CQ) Vs 	AJ (Sens) 
Experiment 4 AS (30CQ) Vs 	AJ (30CQ) 
Fig.8 Development of Mefloquine-ReSiStaflCe 
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were then prepared for starch gel electrophoresis and examined for 
LDH. 	This enzyme was more suitable for examining mixtures than 
6PGD as the parasites of each line produced only a single LIIi band 
which did not overlap in a mixture of the two types. 	6PGD of the 
parasites had three bands. 	Mixtures of the two lines were not easily 
detectable as two of the three bands overlapped. 	As it was important 
to detect differences in the activities of the enzymes from each of 
the two lines, the GPGD enzyme assay was not used. 
(b) Competition 
Competition experiments were carried out in order to discover 
whether there were differences in the growth patterns of the different 
lines of P. chabaudi. 	The competition experiments undertaken are 
shown in Figure 7. 	In each case 1o6 blood forms containing equal 
numbers of each line were injected intraperitoneally into mice. The 
infections were then passaged weekly and either cloned or prepared for 
enzyme analyses (for further details, see Section 3.6.2), 	The Lt1 
enzyme electrophoresis bands of the parasites were examined at various 
intervals to determine whether their relative intensities changed with 
time. 	Cloned parasites were tested for their chloroquine response. 
2.9 	Mefloquine 
2.9.1 	Selection for Mefloquine-Resistance 
Selection of a mefloquine-resistant line of P. chabaudi was under-
taken by exposing parasites to gradual increases of drug pressure (Fig. 8) 
during blood passage through mice. 	This was a similar selection pro- 
gramme to that used for the selection of chloroquine resistance. Three 





A group of mice were each infected with 
10  
parasites of each 
line. 	Three hours after inoculation the first drug treatment was ad- 
ministered at a dose of 7 mg kg 1 for 4 days. 	The parasites which- 
survived the drug treatment were taken and after dilution, 
10  
parasites 
were injected into further mice. 	These mice were treated with a 
slightly higher dose of mefloquine. 	This procedure was repeated using 
higher doses. 	A 4-day suppressive selection programme was adopted 
throughout the selection for mefloquine-resistance. 	Mefloquine- 
resistant lines obtained were also examined for chioroquine-response 
to determine whether an increase in mefloquine-resistance would affect 
its level of chioroquine-resistance, 
2.9.2 	Stability of Mefloquine-Resistance 
Stability studies on the mefloquine-resistant line obtained were 
undertaken. 	The stability of the line on cyclical transmissions 
through mosquitoes and on multiple blood passage without drug pressure 
was investigated. 
2.9.3 	Cross-Resistance to Quinine 
The possibility of cross-resistance between mefloquine and quinine 
was examined. 	Mefloquine-resistant lines were tested with varying 
doses of quinine. 
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3. 	RESULTS 
3.1 Selection of Chioroquine-Resistant Lines 
The parasites responded to selection by a gradual increase in drug 
pressure (Fig. 3). 	The parasites were transmitted through mosquitoes 
as shown to result in the lines AS(15cX), AS(20CQ) and AS(30). 
3.2 	Response of Selected Lines to chioroquine 
3.2.1 	4-Day Versus 6-Day Tests 
A 4-day test was compared with a 6-day test using high doses of 
-1 
the drug (10 mg kg & 30 mg kg
-1
). 	Three lines were compared at each 
dose. 	It was found that even at high doses a '4-day' test did not 
eliminate either the AJ(Sens) or AS(3) lines whereas'6-day' tests were 
more effective (Table 2). 	1 6-day' suppressive drug tests were therefore 
adopted as the standard chioroquine test. These results show that not 
only the dose but the duration of drug treatment is important for anti-
malarial activity. 
3.2.2 	Infectivity During Drug Treatment 
The infectivity of the parasites were examined by subinoculation into 
uninfected mice at various stages of the course of drug treatment (Table 
3). A chloroquine sensitive AJ(Sens) and an AS(3CQ) line were compared. 
On D15 the animals were sacrificed and the blood was used to inoculate 
clean mice. 	The sensitive line was eliminated from the circulation 
after treatment with 5 mg kg- 
1 
 chioroquine for 6 days and could not be 
detected on days 5, 7 and 9 of infection. 	The subinoculations on these 
days confirm the absence of parasites in the peripheral blood (Table 3). 
By B15 the parasites recrudesce at this dose and this observation was 
consistent with the results of the subinoculations. 	The AS(3) line 
TABLE 2. 	Comparison between 4-Day and 6-Day Chioroquine Tests 
% Parasitaemia (± S.E.) 
10 mg kg 
1 
for 4 days 10 mg kg 
1 for 6 days 
Day of Infection D5 D7 D9 D11 D5 D7 D9 	D 11 
AJ(Sens) - - - 
AS(30Q) - - 0.003 0.5 - - - 
(±0.003) (±0.4) 
AS(30CQ) 0.003 3.0 26.0 6.1 0.01 0.2 5.07 	8.5 
(±0.003) (±1.2) (±5.3) (±2.9) (±0) (±0.08) (±1.3) (±3.4) 
Drug Treatment 30 
-1 
mg kg for 4 days 
-1 
30 mg kg for 6 days 
Day of Infection D11 D13 D15 D11 D13 D15 
AJ(Sens) - - 
AS(3CQ) - - 
AS(30CQ) 3.0 16.0 3.0 0.4 7.9 8.3 
(±0.8) (±4.9) (±1.3) (±0.3) (±4.1) (±3.6) 
Drugged animals - mean of 4 mice. 
Undrugged animals were all at Post Peak by DAY 9 of infection 	 0 
± 	0,01% 
TABLE 3. Infectivity of Parasites During Chloroguine Treatment 
Parasjtaemias of donor animals 
Drug Treatment 
(5mg kg/6 days) 
Day of Infection D5 D7 D9 D15 
AJ(Sens) 	DG - - - 0.17±0.17 
tJND 10.3 47 PP PP 
(±2.1) (±6.9) 
AS(3CQ) 	DG - - 0.01 11.02 
(±.0l) (±11.0) 
UND 4.2 36,7 PP PP 
(±2.3) (±13.4) 
Parasitaemias of animals inoculated from drugged mice. 
Days of inoculation 
Day 5 Day 7 Day 9 Day 15 
D6 	D10 	D15 D6 	D13 D15 D5 	D11 	D16 D5 	D10 	D21 
AJ(Sens) - 	- 	- - 	- 	- - 	- 	- 13.3 	+ 
(±2.3) 
± AS (3Q) - 	2.8 	+ - 	+ 	+ - 	+ 	+ 43 	+ 
(±1.7) (±5.8) 
Drugged and subinoculated animals - mean of 3 mice. 
TJndrugged animals - mean of 2 mice. 
PP - Post Peak 
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survived the drug treatment. 	Although parasites could not be detected 
until D9 , the subinoculations show that the parasites were present as 
all the animals subinoculated on D 5 showed positive infections (Table 
3). 	These results confirm that at this dose (5 mg kg 1) a difference 
can be detected between the AJ(Sens) and AS(3Q) lines; the AS(3Q) 
line remains infective whilst the AJ(Sens) line exhibits a reduced in-
fectivity. 
Both lines were treated in the same way using a higher dose of 
10 mg kg-1  chloroquine for 6 days; none of the parasites survived the 
drug treatment and all the subinoculations showed negative results. The 
mice were examined up to D 15 in each case. 	On D15 the mice were sacri- 
ficed and subinoculated into uninfected mice as before; these gave 
negative results as well. 	Thus, it would seem that this dose eliminates 
these two lines completely (see Table 4 also). 
3.2.3 	Drug Delay Tests 
Drug delay tests were devised to observe the rate of decline of 
parasites of different lines during drug treatment using doses of 10 mg kg
- l 
and 20 mg kg- 
1 
 given for 4 days. 	The AJ(Sens), AS(3CQ), AS(15CQ) and 
AS(300Q) lines were compared. 	The AJ(Sens) and AS(30) lines declined 
rapidly after treatment at both doses. 	The parasites do not increase 
in numbers again until D 15 . 	The AS(15CQ) line grew in the presence 
of the drug at a dose of 10 tag kg- 
1, 
 however on prolonged exposure the 
parasite numbers decreased rapidly by D 5 . 	Once drug pressure was re- 
leased the parasites grew rapidly to reach a high parasitaemia by D13 . 
Drug treatment at the higher dose of 20 mg kg 1 gave a similar result 
with the exception that the parasites declined rapidly soon after ex- 
posure to the drug. 	The parasites of the AS(300) line grew in the 
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Data from Table 36 (In appendix) 
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parasites were suppressed. Once drug pressure was released the para-
sitaeniia increased exponentially reaching a peak by D 8 . 	Although the 
initial parasitaexnias of the lines used were different, the test shows 
some clear differences between the lines. 	The AJ(Sens) and AS(30) 
lines were indistinguishable from each other, however they were clearly 
different from the high levels of resistance. 	The AS(15Q) and AS(3OcQ) 
lines differed in their response. 	The rate of suppression of the 
AS(30Q) line was slower than that of the AS(15CQ) line; the former 
continued to recrudesce earlier once drug pressure was removed than the 
iatter.(Figs. 9 & 10). 
3.2.4 	Response to Different Doses of chloroquine 
The most convincing evidence for different levels of chloroquine-
resistance was that obtained from drug tests with chloroquine at varying 
doses (Table 4). 	A dose of 3 mg kg- 
1 
 did not always distinguish between 
the lines (Table 37, in Appendix); at a dose of 5 mg kg 1 the sensitive 
lines could be differentiated from the low level (AS(3CQ)) and higher 
levels. 	A dose of 30 mg kg- 
1 
 of the drug revealed differences between 
the higher levels of resistance. 	The most significant result was the 
rate at which the parasites emerged after drug treatment. 	The AS(300) 
line almost always emerged before the other lines. 	At this high dose 
of 30 mg kg- 1 the parasites of the AS(30O) line recrudesced by D 9 . 
The parasites of AS(20Q) line emerged by D11 , followed by those of 
AS(15Q) line at D13 . 
These tests were used in subsequent genetic work. 	Clones of unknown 
chloroquine response were tested at 30 mg kg- 1. 	If the parasites 
emerged by D9 or D11 they were considered to be in the 30Q class; those 
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4 	 s 5 5 	1 6 	1 t 	S I 
- - 	- 	0.115 	1.9 	1.5 1.7 	0.1 
11.1)2) 	()).l)±)(0.09)(l).8) 	(0 . (X)7) ( . 01 (0.05)(0.63)(0.(d((O.005) (0.02) 	(0.4) 	(0.7)(0.3) 40.0071(0.2) 	(0.9) 	(0.11) 
I 
(((.01) 	(0.2) 	(0.7)(0.9) 
6 	I 	I I 
(11():0 (0.0 	(11.4) ((.2)  
UndroggecI - mean 01 12 mice. 
('rugged - moan of 5 mIce. 
IN 
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which emerged later,on either D13 or D15 , were grouped in the 15 
class. 	Parasites which survived treatment at 3 mg kg- 
1 
 chloroquine 
but failed to survive either 15 or 30 mg kg- 
1 
 of the drug were classi-
fied as 3CQ parasites. 
3.3 	Stability of Resistance of Selected Lines 
3.3.1 	Response of AS(15CQ) Line 
The resistance of the AS(15CX) line was stable following mosquito 
transmission (Table 5), and after multiple blood passage in the absence 
of the drug. 	The resistance appeared to increase after passage. This 
may be either due to experimental error or indeed an increase of virulence 
due to continued blood passage. 	However, an increase in virulence is 
unlikely to occur in two weekly passages; nevertheless, this possibility 
cannot be ruled out. 
3.3.2 	Response of AS(20X) line 
The AS(2000) line was stable after mosquito transmission (Table 6). 
This line was found to be stable on multiple blood passages without 
drug pressure. There seemed to be an increase in virulence from 
passages 2 to 8. 	This may be due to blood passage. 	An alternative 
explanation is, as this line was uncloned at this stage, the population 
may consist of different levels of resistance and the high levels of 
resistance may be outgrowing the lower levels producing the results ob-
tained. 
3.3.3 	Response of AS(30) Line 
Four clones were established from this line and tested for drug 
resistance at 30 mg kg- 
1 
 (Table 7) . 	Clone numbers 1 and 3 were classi- 
fied as 300D and clone numbers 2 and 4 as 150 (See 3.2.4). 	The AS(300Q) 
46. 
TABLE 5. 	Stability of AS(15cQ) line after Mosquito Transmission 
% Parasitaemia(± S.E.) 
AS(15CQ) AS(3CQ) CONTROL 




0.17 (±0.08) 	PP 
	
DO 	UND 
- 	 pp 5 
7 2.6(±.1.6) 	PP - 	 pp 
DO : Drugged Animals, Mean of 3 Mice, Treated with 15 mg kg- 1 
chioroquine for 6 days. 
tJND: Undrugged Animals, Mean of 2 Mice. 
PP : Post Peak. 
47. 
TABLE 6. Stability of AS(20cQ) Line After Mosquito Transmission 
% Parasitaeinia(± S.E.) 
AS ( 15CQ) AS (300) CONTROL 
Day of Infection D11 D11 
Passage No. 
after mosquitoes UND 
0.2(±0.2) 	Pp 
	
DG 	 UND 
- 	 PP 2 
8 3.2.(±1.6) 	PP - 	 PP 
14 2.5(±0.5) 	PP - 	 PP 
DG : Drugged animals, mean of 5 mice treated with 20 mg kg- 1 
chioroquine for 6 days. 
UND: Undrugged animals, mean of 2 mice. 
PP : Post Peak. 
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TABLE 7. Drug Response of Clones Derived from the AS(3OCQ) Population 
% Parasitaeniia(± S.E.) 
DRUGGED* UNDRTJGGED 




1 0.17(±0.08) 	1.0(±0.3) 42(±18.4) 
2 - 	0.05(±0.01) 50(±O) 
3 0.09(±0.01) 	0.8(±0.2) 22(±5.0) 
4 
0 	- 0.06(±0.035) 23.5(±18.4) 
AS(3CQ) Control - 	 - 42(±14.9) 
* Drugged Animals - mean of 3 mice, treated with 30 mg kg- 
1 
 for 6 days. 
+ Undrugged Animals - mean of 2 mice, 
Fig.11 Stability of the AS(30C0) Line 
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RAT 	IUtIIIIIIIII CROSS 1 
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Figi2aThe Response of Different Lines of P Chabaudi to Mefloquine (7mg kg -1) 
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population was probably a mixture of different levels of resistance, 
which had survived the drug treatment. 	Clone No. 3 was used for 
further stability studies (Fig, 11) , and was subsequently used for 
genetic analyses. 	As seen from Figure 11, this clone was stable 
through many blood passages in the absence of the drug (Table 8). 
3.4 Response of Selected Lines to Other Drugs 
3.41 Response to Mefloquine 
Using the 1 4-day' suppressive drug test, the different chioroquine-
resistant lines of P. chabaudi were treated at two doses of mefloquine 
(7 and 10 mg kg 1). 	An AS(30MF) line was used as a control (see Section 
3.8). 	The higher dose of 10 mg kg- 1 mefloquine eliminated all of the 
parasites apart from the control. The response to 7 mg kg- 
1 
 mefloquine 
showed some degree of cross-resistance between this drug and chloroquine 
(Fig. 12a.and Table 9). A difference could be distinguished between the 
low level of chioroquine-resistance AS(30) and the higher levels; the 
AS(3O) line responded like the sensitive lines. The AS(150Q) and the 
AS(200Q) lines could be compared as the control values indicate that 
equal numbers of parasites were Inoculated. 	The AS(200Q) parasites 
emerged before those of the AS(15cQ) line. 	From the results, three 
classes can be distinguished with this test. 	These are: 
AJ(Sens), AS (Sens) and AS(3XD. 
AS(15CQ). 
AS(2OCQ) and AS(30(Xi). 
3.4.2 	Response to Mepacrine 
The response of different lines to a'4-day' suppressive test using 
13 and 15 mg kg- 1 mepacrine was investigated. 	A dose of 15 mg kg- 1 
50. 
TABLE S. 	Stability of the AS(30) Line (Clone 3) After Multiple 
Blood Passage. 
% Parasitaemia(± 	SE.) 
AS(300Q) AJ(Sens) CONTROL 
DG UND DG UND 
Day of Infection D9 	D11 	D13 D9 D9 	D11 	D13 D9 
Passage No. after 
mosquitoes 
10 - 	0.5 	3.5 7.15 - 	- 	- PP 
± ± ± 
(0.3) 	(1.4) (2.12 
12 0.05 	0.9 	4,0 PP - 	- 	- PP 
± ± ± 
(0.035) 	(0.6) 	(2.7) 
14 0.003 	1.0 	11.00 PP - 	- 	- PP 
± ± ± 
(0.003) 	(1.2) 	(5.9) 
16 0.025 	1.3 	8.4 PP - 	- 	- PP 
± ± ± 
(0.003) 	(1.5) 	(5.3) 
18 0.06 	3.5 PP - 	- 	- PP 
± ± 	± 
(0.035) 	(1.5) 
21 0.01 	0.4 PP - 	- 	- PP 
± ± 
(0.01) 	(0.4) 
DG 	 Animals, mean of at least 3 mice treated with 30 mg kg
-1 
chioroquine for 6 days. 
UND: Undrugged animals, mean of 2 mice. 
Legend as for Figure 11, 
TABLE 9. 	Response of Different Lines of P. chabaudi toMefloquine 
% Parasitaemia(± S.E.) 
Day of Infection D5 07 	D9 	D11 D13 D15 UND 07 
LINES 
AJ(Sens) - - 	- 	 - - 0.02(±O) 56(±O) 
AS(Sens) - - 	- 	 - - 0.1(±0.04) 40(±13) 
"N 
AS(3CQ) - - 	- 	 - - - 46(±2.1) 
CID 
11 0 AS(15X) - - 	- 	 - 	0 08(±0.01) 0.9(±04) 27(±8.0) AS(20Q) - - 	- 	0.006(±0.004) 	0.6(±0,3) 2.3(±0.9) 24(±2.9) 
AS(30cQ)Population - - 	- 	0.07(±0.07) 	1.5(±1.3) 2.5(±0.7) 51.3(±1.2) 
AS(30MF) ). 2 (±0.05) OJ5(±1..5) 	5.0(±1,5) 	74(±2.0) 	1.5(±0.6) 0. 4(±0.2) 10.5(±3.0) 
Drugged Animals ,mean of 5 mice treated with 7 	mg kg 
-1
Mefloquine 
UND: Undrugged Animals, mean of 4 mice. 
Legend as for Figure 12a. 
I-I 
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eliminated the parasites of all the different lines tested. 	Using a 
dose of 13 mg kg- 
1 
 the data indicated that the AS(Sens) and AS(30Q) 
lines were more sensitive to the drug than those showing higher levels 
of chloroquine-resistance (Table 10). 	However, this test could not 
distinguish between the AS(15Y) and AS(30c.X) lines. 
3.4,3 	Response to Quinine 
Three lines were investigated using a 1 4-day' suppressive test 
with different doses of quinine. 	Although these tests could distinguish 
between the chioroquine-resistant and chloroquine-sensitive lines, thus 
demonstrating cross-resistance between the two drugs, they could not 
differentiate between the high levels of resistance (Table 11). 
3.5 	Genetic Analyses 
The AS(30CQ) line was used for genetic analyses in order to deter-
mine the genetic basis of this high level of resistance. 	As the way 
in which the high level of chloroquine -resistance was obtained involved 
a gradual increase of drug pressure, a series of several mutations may 
have been involved in producing this line. 	This hypothesis was tested 
by crossing the AS(30C) line with chloroquine-sensitive lines. 
3.5.1 	Crosses 1 & 2: AJ(Sens)x AS(30) 
These crosses were conducted as shown in Figure 12. On D after 
the mosquitoes had engorged, five mosquitoes of each of the crosses and 
control cages were dissected and examined for oocysts. 	All of the 
cages contained infected mosquitoes. 	The parent lines each formed ap- 
proximately equal numbers of oocysts. 	The mosquitoes were allowed to 
TABLE 10. 	Response of Different Lines of P. chàbaüdito Mepacrine 
% Parasitaemia(± S,E O ) 
I II 
Day of Infection D5 D7 D9 D11 UND D7 D5 D7 D9 D11 UND 
AS(Sens) - - - - 34 - - - - 39 
± ± 
(14.1) (3.5) 
AS(3CQ) - 0.02 2.6 22 PP - - - - 52 
± ± ± ± 
( 0 .017) (2.2) (13.9) (1.5) 
AS(15Q) 0.05 0.8 20 29 43 - 0.003 0.03 0.2 33 
± ± ± ± ± ± ± ± ± 
(0.02) (0.18) (5.2) (3.5) (1.0) (0.003) (0) (0.03) (12.0) 
AS(30cx) 0.003 0.22 1.35 11.7 32 - 0.05 1.23 13.3 Pp 
± ± ± ± ± ± ± ± 
(0.0035) (0.2) (0.4) (3.5) (2.8) (0.03) (0.4) (6.4) 
Drugged Animals - Mean of 3 Mice, Treated with 13 mg kg for 4 days. 
UND: Undrugged Animals - Mean of 2 Mice. 
PP : Post Peak 
I & II : Test Number. 
TABLE 11. 	Response of Different Lines of P. chabaudi to Quinine 
% Parasitaemia(± S.E,.) 
Dose (mg kg- 
1 
 for 
150 200 250 
4 days)  
Day of infection 06 D8 D10 UND 06 D6 	D8 	D10 UND 06 06 	
D8 	D10 UND D6 
AJ(Sens) - - 0.3 20 - 	- 	0.1 13 - 	0.02 	0.6 4.0 
± ± ± ± ± ± ± 
(0.2) (7.8) (0.11) (0) (0.02)(0.6) (0) 
AS(15Q) 0.8 12 PP 38 - 	0.13 	5.6 30 0.007 0.61 14.8 
± ± ± ± ± ± ± 	± ± 
(0.4) (6.3) (2.0) (0.07)(3.6) (8.1) (0.009)(04) (5.2) 
S(300) 0.7 9.4 10,7 45 - 	0.33 	7 4.8 - 	0.04 	0.11 2.2 
± ± ± ± ± ± ± ± ± ± 
(0.3) (2.3) (0.5) (5.0) (0.2) 	(2.9) (4.0) (0.04)(0.08) (0.1) 
Drugged animals - mean of 3 mice. 
UND: Undrugged animals - mean of 2 mice. 
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reinfect mice on D15 and D17 of the mosquito infections. 	The blood 
forms emerged between days 4 - 7, were passaged into clean mice and 
deep frozen. 
3.5.2 	Tests on Unclonec! Progeny 
The progeny of the crosses were examined for their response to 
pyrimethamine and chloroquine (30 mg kg 1) and the parasites surviving 
the drug treatments were examined for theirenzyme types (Fig. 12). Drug 
treatment should have eliminated all of the sensitive parasites. 	The 
presence of both enzyme types following administration of drugs indicated 
that exchange of genetic material had occurred; in the absence of 
'recombination', only enzyme types LDH-3 and 6PGD-2 would have been 
present, being characteristic of the drug resistant parasites. 
Parasitaemias of crosses 1 and 2 following treatment with chloroquine 
-1 
at 30 mg kg are shown on Table 12 
3.5.3 	Control Studies 
Clones were established from the two parental lines transmitted 
as controls for Cross 1. 	Of 100 mice inoculated, 14 clones of the 
AS(30CQ)parent line were obtained. 	These clones were analysed for their 
enzyme types and drug resistance and were found to have the phenotypes 
expected of the parent AS (300Q) line (Table 1). 
Six clones of the AJ(Sens) control were established from the ino-
culation of 50 mice. 	The phenotypes of these clones were those expected 
of the AJ(Sens) line (Table 1). 
The absence of recombinant classes in these control studies indicate 
that mutation events were unlikely to account for the recombinant classes 
obtained from crosses 1 and 2. These classes could thus be presumed to 
TABLE 12. 	Response of the Uncloned Products of Crosses 1, 2 after Multiple Blood Passage 
% Parasitaemia(± S.E.) 
Line Passage D9 D11 D13 D15 Passage D9 D11 D13 D15 
No.  No.  
Cross 1 5 0.002 0.075 0.3 - 10 - - - 0.2 
± •± ± ± 
(0.002)(0.05) (0.2) (0.2) 
Cross 2 6 - - 0.04 1.1 11 - - - 0.09 
± ± ± 
(0.02) (0,4) (0.06) 
300Q Control 6 0.6 4.9 0.9 - 12 0.7 9.5 11.3 - 
± ± ± ± ± ± 
(0.2) (2.3) (0.7) (0.4) (5.5) (6.4) 
AJ Control 6 - - - -. 12 - - - - 
Drugged Animals - mean of 4 mice, treated with 30 mg kg 1 chloroquine for 6 days. 
Undrugged Animals of each line showed post peak parasitaemlas on D9 
C) 
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have arisen following cross-fertilization of the two parental types. 
3. 5.4 	Characterization of Clones Derived from Cross 1 
Unselected Clones 
On cloning the progeny of Cross 1, 33 clones were established from 
a total of 350 mice inoculated. 	Each clone was examined for its enzyme 
type and drug response, the results of which are shown in Table 13. 
The 16 possible combinations are represented by groups A - P. 	Only 7 
of the classes are represented among the progeny of which there is a 
preponderance of the AJ(Sens) parental types (Group A) compared with 
any other class. 	10 of the 33 clones were found to be resistant to 
chloroquine. 	The chloroquine-resistant clones were tested at doses of 
3 mg kg 1 , 15 mg kg 1 and 30 mg kg 1 . 	9 of the 10 clones were resistant 
to a low level (3 mg kg ') whereas one of the clones was resistant to an 
-1 
intermediate level (15 mg kg ) (Table 13). 	These clones were classified 
according to the criteria defined in Section 3.2,4. 
Selected Clones 
To attempt to obtain more highly resistant clones from the progeny 
of the cross, uncloned parasites were treated with chloroquine at various 
doses. 	Clones were then established after drug treatment and examined 
for the four markers, particularly their level of chloroquine-resistance. 
This was measured by conducting drug tests at two doses of the drug, 
3 mg kg 
-1 
 and 30 mg kg- 1. 	The higher dose differentiated bétween high 
levels of chloroquine.-resistance; parasites were classified according 
to the rate at which they produced patent parasitaemias after drug 
treatment (see Section 3.2.4) as either 15 	or 30CQ clones. 
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TABLE 13. 	Characterization of Clones Established from the 
Unselected Products of Cross 1, 
AJ (Sens): 	LIi-2, 6PGD-3, PYR-S, CC.) -S 
X 	AS (30CQ) 	:LDH-3,_6PGD-2, PYR-R, 	Q-R (30). 
LDH 	6PGD 	PYR 	CQ 	No. of Clones 
A 2 3 S S 19 
B 2 3 S R(3) 1 
C 2 3 R S 0 
D 2 3 R R. 0 
E 2 2 S S 3 
F 2 2 S R(3) 1 
G 2 2 R S 0 
H 2 2 R R, 0 
I 3 3 S S 0 
J 3 3 S R, 0 
K 3 3 R S-- -0 	- 
L 3 3 R R' 0 
M 3 2 S 5 0 
N 3 2 S R(3) 2 
0 3 2 R S 1 
P 3 2 R R(3) 5 
R(15) 1 
TOTAL NO. OF CLONES 	33 
R : Resistant to Drug Tests (see Section 3.2.4) and classified at 
the levels bracketed for CQ. 
S : Sensitive to 3 mg kg- 
1 
 CQ for 6 days or 15 mg kg- 
1 
 PYR for 4 
days. 
LIE 2 or 3 : Variants of enzyme lactate dehydrogenase, 
6PGD 3 or 2 : Variants of 6-phosphogluconate dehydrogenase, 
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Selection at 3 mg kg- 1 chloroquine 
After treating the progeny of the cross with 3 mg kg- 
I 
 chloroquine 
for 6 days, the surviving parasites were cloned. 	15 clones were ob- 
tained from inoculating 200 mice; of these 2 were found to be chloroquine-
sensitive and 13 were chioroquine-resistant (Table 14). 	12 of the re- 
-1 
sistant clones were resistant to a low level (3 mg kg ) while one of 
the clones was resistant to an intermediate level (15CQ). 	The stability 
of the 15CQ clone obtained was examined further. This clone was presumed 
to be a product of cross-fertilization as it demonstrated an intermediate 
(15cQ) level of chloroquine-resistance. 	This clone was found to be 
stable after 6 blood passages in the absence of the drug (Table 20) and 
maintained its level of resistance. 
Selection at 15 mg k9_ 1 chloroguine 
Two courses of treatment were given. 	Firstly, the drug was ad- 
ministered for only 5 days before cloning in the hope that a wide range 
(unpublished) 
of recombinant classes would be obtained; previously it had been found/ 
that 1 5-day' cliloroquine drug tests were not sufficient to eliminate 
sensitive parasites. 	The phenotypes of the 12 clones (from inoculating 
a total of 100 mice) 	obtained following this treatment, are shown 
on Table 15. 	It can be seen that there is an absence of the highly 
resistant (30) class. 
-1 
Secondly, 15 mg kg of the drug was administered for 6 days before 
cloning, 	8 clones were derived from inoculating 50 mice. 	The pheno- 
types of the clones are shown on Table 16. 	7 clones were classified 
as 15CQ and 1 clone was like a parental AS(30CQ) type. 
TABLE 14. Characterization of Clones Established from Cross 1 
Selected at a Low Level (3Q/6 days). 
AJ (Sens): LDH-2, 6PGD-3, PYR-S, CQ-S 
X AS (30X) : LDH-3, 6PGD-2, PYR-R, cQ-R(30). 
I LDH 	I 6PGD I 	PYR 	 cQ 	I No. of Clones 
A 2 3 S S 1 
B 2 3 S R(3) 3 
C 2 3 R S 0 
D 2 3 R R, 0 
E 2 2 S S 0 
F 2 2 S R 0 
G 2 2 R S 0 
H 2 2 R R. 0 
I 3 3 S S l 
J 3 3 S R.. 0 
K 3 3 R S 0 
L 3 3 R R(3) 1 
M 3 2 S S 0 
N 3 2 S R(3) 2 
0 3 2 R S 0 
P 3 2 R R(3) 6 
H It ti R(l5) 1 
60. 
TOTAL NUMBER OF CLONES 	15 
SEE TABLE 13 FOR KEY. 
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TABLE 15. 	Characterization of Clones Established from Cross 1 
Selected at an Intermediate Level (15Q/5 days). 
AJ (Sens) 	LI-2, 6PGD-3, PYR-S, CQ-S 
X 	AS (30CQ) 	: LLflI-3,_6PGD-2, PYR-R, CQ-R (30). 
LDH 	6PGD 	PYR 	CQ 	No. of Clones 
A 2 3 S S 2 
B 2 3 S R(3) 5 
C 2 3 R S 0 
D 2 3 R R(3) 1 
R(15) 1 
E 2 2 S S 0 
F 2 2 S R , 0 
G 2 2 R 5 0 
H 2 2 R R(15) 2 
I 3 3 S S 0 
J 3 3 5 R , 0 
K 3 3 R S 0 
L 3 3 R H 0 
M .3 2 S S 0 
N 3 2 S R. 0 
0 3 2 R S 0 
P 3 2 H R(15) 1 
TOTAL NUMBER OF CLONES 	12 
SEE TABLE 13 FOR KEY. 
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TABLE 16. 	Characterization of Clones Established from Cross 1, 
Selected at an Intermediate Level (15 	for 6 days). 
AJ (Sens) 	: LDH-2, 6PGD-3, PYR-S, CQ-S 
X 	AS (30Q) 	: LDH-3, 6PGD-2, PYR-R, CQ-R (30). 
LDH 	6PGD 	PYR. 	CO. 	No. of Clones 
A .2 3 S S 0 
B 2 3 S R: 0 
C 2 3 R S 0 
D 2 3 R R. 0 
E 2 2 S S 0 
F 2 2 5 R 0 
2 2 R S 0 
H 2 2 R R, 0 
I 3 3 S 5 0 
J 3 3 S 0 
K 3 3 R S 0 
L 3 3 R 0 
M 3 2 S S 0 
N 3 2 S R 0. 
0 3 2 R 5 0 
P 3 2 R R(15) 7 
R(30) 1 
TOTAL NUMBER OF CLONES 	8 
SEE TABLE 13 FOR KEY. 
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(iii) Selection at 30 mg kg- I Chloroguine 
29 clones were obtained from a total of 120 mice inoculated after 
drug treatment at 30 mg kg- 
1 
 for 6 days. 	The phenotypes of the clones 
are shown on Table 17. 	It can be seen that all of the clones obtained 
were recombinant, with enzyme types of the sensitive parent (LDH-2, 
6PGD-3) 2 of the clones were resistant to an intermediate level 
(15cQ) and the remaining 27 clones to a high level (30CQ). 
Two of the clones which were resistant to a high level (300) 
were examined for stability on multiple blood passage without drug 
pressure. These clones were found to be stable in their chloroquine 
resistance at the. high level (Table 20). 
Tables 18 and 19 summarize the chloroquine response and enzyme 
types of all the clones derived from Cross 1. 
3.5.5 	Characterization of Clones from Cross 2 
Cross 2 was a repetition of Cross 1. 	21 clones were obtained from 
the progeny of the cross, each of which was examined for the character-
istics involved. 	Their phenotypes are shown in Table 21. 	It can be 
seen that while the enzyme markers segregated randomly, all of the 
clones were pyrimethamine-sensitive. 	14 of the clones were chioroquine- 
resistant. 	A range of levels of chloroquine-resistance was obtained. 
3.6 Reconstruction and Competition Experiments 
3.6.1 	Reconstruction 
In order to determine how sensitive the electrophoretic system is 
at determining quantitative differences, reconstruction experiments were 
carried out. 	Known mixtures of the two LDH enzyme types (2 & 3) were 
made and examined on gels (Table 22). 	Both forms of LDH could be 
64. 
TABLE 17. 	Characterization of Clones Established from Cross 1, 
Selected at a High Level (30Q for 6 days). 
AJ (Sens) : LDH-2, 6PGD-3, PYR-S, CQ-S 
X 	AS (30Q) 	: LDH-3, 6PGD-2, PYR-R, cQ-R (30). 
LDH 	6PGD 	PYR 	CQ 	No, of Clones 
A 2 3 S S 0 
B 2 3 S R(30) 1 
C 2 3 R S 0 
D 2 3 R R(15) 2 
R(30) 26 
E 2 2 S S 0 
F 2 2 S 0 
G 2 2 R S 0 
H 2 2 R R 0 
I 3 3 S S 0 
3 3 3 S 0 
K 3 3 R S 0 
L 3 3 R R 0 
M 3 2 S S 0 
N 3 2 S 0 
0 3 2 P. S 0 
P 3 2 R 0 
TOTAL NUIER OF CLONES 	29 
SEE TABLE 13 FOR KEY. 
TABLE 18. Chioroguine Response of Clones Established from 
Cross 1. 
No. of Clones 
Method of Selection 
Sens 30Q 15Q 30Q Total 
Unselected 23 9 1 0 33 
Selected at 3CQ/6 
2 12 1 0 15 
days 
Selected at.15CQ/5 
2 6 4 0 12 
days 
Selected at 15CQ/6 
7 1 8 days 
Selected at 30Q/6 
0 0 2 27 29 
days 
Total No. of Clones 27 27 15 28 97 
SENS: Sensitive to 3 mg kg- 
1 
 CQ for 6 days. 
3Q : Resistant to 3 mg kg- 
1 
 CQ for 6 days, and sensitive to 30 
mg kg for 6 days. 
15Q: Resistant to 30 mg kg- 
1 
 CQ for 6 days, positive infections 
on D13 or D15 . 
30CQ: Resistant to 30 mg kg- 1 CQ for 6 days, positive infections 
on D9 or D11, 
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TABLE 19. Enzyme Types of Clones Obtained from Cross 1. 
Enzyme Types No. of Clones 
LDH-2 6PGD3 62 
LDH-2 6PGD-2 6 
LDH-3 6PGD-3 2 
• 	LDH-3 6PGD-2 27 
Totalnumber of clones 	• 97 
*-Parental types 
TABLE 20. 	Stability of Progeny of Cross 1. 
% Parasitaemia(± 5.E)* 
Passage No. 6 11 
Day of Infection 09 
D 1 013 
D15 TJND D9 09 D11 013 D15 	UND 09 
AJ(Sens) Control - - - - PP - - - - 	Pp 
AS(300) Control 0.6 4.9 0.9 PP 0.7 14.5 11.3 pp 
± ± ± ± ± ± 
(0.2) (2.3) (0.7) (0.4) (5.5) (6.4) 
15CQ (selected at 0.6 3.2 
3Q) Clone from - - ± ± PP 
Group P (Table 14) (0.037) (2.3) 
30 	(selected at 0.07 7.6 PP PP 0.03 2.3 26 PPP 
30CQ) Clone from ± ± ± ± ± 
Group D (Table 17) (0.01) (1.4) (0.01) (0.8) (18) 
30CQ (selected at 0.025 1.5 8.8 0.03 1.7 
30CQ) Clone from ± ± ± PP - ± ± PP 
Group D (Table 17) (0.025) (0.4) (1.3) (0.03) (0.6) 
* Drugged animals - mean of 3 mice, treated with 30 mg kg 
-1 
 for 6 days. 
UND: Undrugged animals - mean of 2 mice. 
PP : Post peak. 
-1 
TABLE 21. Characterization of Clones Established from the 
unselected products of Cross 2. 	 - 
AJ (Sens) 	LDH-2, 6PGD-3, PYR-S, cQ-S 
X AS (30cQ) : L1-3, 6PGD-2, PYR-R, CQ-R (30)0 
I LDH 	6PGD 	PYR 	CQ 	No. of Clones 
A 2 3 S 5 5 
64 
R(3) 2 
B 2 3 S R(15) 3 
R(30) 1 
C 2 3 R S 0 
D 2 3 R R' 0 
E 2 2 S S 0 
F 2 2 S R 0 
G 2 2 S R 0 
H 2 2 R 0 
I 3 3 S S 0 
J 3 3 S R(3) .1 
R(15) 1 
K 3 3 R S 0 
L 3 3 R H:: 0 
M 3 2 S S 2 
R(3) 4 
N 3 2 S R(15) 0 
R(30) 2 
0 3 2 H S 0 
P 3 2 R H' 0 
TOTAL NUMBER OF CLONES 	21 
R : Resistant to Drug Tests (see Section 3.2.4) and classified at 
the levels bracketed for CQ. 
S : Sensitive to Drug Tests. 
LDH 2 or 3 - variants of lactate dehydrogenase. 
6PGD 3 or 2 - variants of 6 phosphogluconate dehydrogenase. 
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TABLE 22. 	Reconstruction Eçperiments to Determine the Sensitivity 
of the Eleátrophoretic System 
Experiment No. % AS % AJ 
RUN 
LDH 
I RUN II 
1 100 0 3 3 
2 90 10 3>>2 3>>2 
3 80 20 3>2 3>2 
4 70 30 3=2 3>2 
5 60 40 3=2 3=2 
6 50 50 2=3 2=3 
7 40 60 2=3 2=3 
8 30 70 2=3 2=3 
9 20 80 2>3 2>3 
10 10 90 2>>3 2,>>3 
11, 0 100 2 2 
LDH 2 & 3 - Electrophoretic variants of lactate dehydrogenase. 
I, II - Duplicate gel runs on the same samples. 
= : Denotes no detectable differences between the intensities of 
the bands. 
> : Means that differences In intensities can just be detected. 
>>: Means that differences in Intensities of the bands can clearly 
be detected. 
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detected in the mixtures even when the proportion of one line was as 
low as 10%. 	No difference in intensity was apparent at 60:40. Pro- 
portions of 80:20 were readily detectable. 	A mixture in the proportion 
70:30 gave fluctuating results; in some cases no differences could be 
detected. 	This level of difference may be the critical level at which 
the system can detect differences of varying quantities of mixtures. 
3,6.2 	Competition 
Competition experiments were carried out to determine whether there 
were any differences in growth between the parasite lines used in this 
work which might account for some of the results obtained. Competition 
experiments were conducted between several lines as follows: 
Experiment 1: - AJ(Sens) Vs AS(Sens) 
Dilutions of parasites of each line were made so that 0.1 ml of 
inoculum contained 
10  
parasites. 	The parasites were then mixed in 
equal volumes and 0.1 ml amounts were injected into a group of mice. 
Parasites from the infections were passaged weekly; on each occasion 
i 10 
6  parasites were inoculated into each uninfected mouse. 	At various 
weekly intervals shown on Table 23 (passage no.), the parasites were pre- 
pared for electrophoresis and examined for their LDH types. 	After 
about 9 weekly passages the AJ enzyme type (LDH-2) appeared to outgrow 
the AS enzyme type (LDH-3). 	This suggested that the AJ(Sens) parasites 
were at a selective advantage in competition with AS(Sens) forms. 
Experiment 2: 	AS(0Q) Vs AS(3000) 
These two lines were identical in their enzyme types and pyri-
methamine sensitivity but differed in their resistance to chloroquine. 
As in the previous experiment, equal numbers of parasites were mixed so 
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TABLE 23. 	Experiment 1 - Competition studies between Blood 
Forms of a 50:50 Mixture AJ(Sens) and AS(Sens) Lines. 
Passage No LDH 
RUN I RUN II RUN III 
1 2=3 2=3 
3 2=3 2=3 
9 2>3 2>3 
11 2>3 2>3 2>3 
12 2>>3 2>>3 2>>3 
SEE TABLE 22 FOR KEY 
I, II, III: Replicate gel runs on the same samples. 
72. 
that an inocu].um of 
10  
contained 0.5 x 
10  
parasites of each type. 
Four mice were injected with a mixture of 10  parasites. 	The parasites 
from resulting infections were passaged at weekly intervals. At various 
periods shown on Table 24, the mixture was cloned and analysed for 
chloroquine-resistance by using '6-day' drug tests at doses of 3 mg kg- I 
and 30 mg k9­  1. 	After 17 weekly passages a total of 18 resistant (30CQ) 
clones were obtained compared to 4 sensitive clones. 	On passage numbers 
4 and 9, the mixture was treated with 4 mg kg- 1  chloroquine for 6 days. 
The parasites which survived the treatment were cloned; all of the 7 
clones established were resistant to a high level (30 mg kg 1) of the 
drug (Table 24). 
Experiment 3: - AS(30CQ) Vs AJ(Sens) 
As in Experiment 1, a 50:50 mixture of blood forms of the two lines 
was made so that 0.1 ml of inoculuin contained 0.5 x 10  parasites of 
each line. 0.1 ml of the mixture was then inoculated into each of 4 
mice. 	The parasites were passaged at weekly ,  intervals thereafter. 
At various periods shown on Table 25, the parasites were prepared for 
starch gel electrophoresis and examined for their LIE types. 	On 
passage number 12, the parasites were tested at 30 mg kg- I  chloroquine 
for 6 days and the surviving parasites were examined for their LDH en- 
zyme type. 	Only the parasites of the highly resistant line (LIZ-3) 
survived the treatment, showing that the two lines had remained 
separate. Had any exchange of characters taken place both types might 
have been detected following drug treatment. In competition these two lines 
demonstrated the same selective advantage. 
Experiment 4: - AJ(30) Vs AS(30) 
The AJ(300) line was a product of Cross 1, therefore its character-
istics apart from the four markers (Group D in Table 17) were unknown. 
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TABLE 24. 	Experiment 2 - Competition Studies Between Blood 
Forms of a 50:50 mixture of AS(0) and AS(30CQ) 
Lines 
Passage No. No. of mice 
inoculated 
No. of sensitive 
Clones+ 
No. of resistant 
Clones* 
4* 30 0 1 
7 50 1 2 
9* 91 0 6 
15 75 3 4 
17 53 0 12 
* Treated with 3 mg kg- 1 prior to cloning. 
+ 	 -1 Sensitive to 3 rug kg 	Q for 6 days. 
* Resistant to 30 rug kg- I cQ for 6 days. 
TABLE 25. Experiment 3 - Competition Studies Between Blood 




RUN I RUN II RUN III 
1 2=3 23 
3 2=3 2=3 
7 2=3 2=3 
1]. 23 2=3 
12* 3 3 
17 3>2 3>2 
19 2=3 2=3 2=3 
20 3>2 2=3 2=3 
SEE TABLE 22 FOR KEY 
I, II, III: Replicate gel runs on the same samples. 
* After treatment with 30 mg kg- I eQ for 6 days. 
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As all of the highly chioroquine-resistant clones (30O) obtained from 
Crosses 1 and 2 apart from one were recombinant, the question of whether 
recombinants were more 'vigorous' was investigated. 	As in Experiment 1 
a 50:50 mixture of the blood forms of the two lines was made so that 
each mouse was inoculated with 0.5 x 
10  
parasites of each line. 	This 
mixture was passaged weekly and its LDH enzyme types examined at inter- 
vals (Table 26). 	The results suggest that the recombinant line was at 
a selective advantage over the parental AS(30Q) line; the LDH-2 (AJ) 
enzyme type seems to be demonstrating greater activity than the L1!-3 
(AS) enzyme type as passaging continued. 
3.7 In vitro Chloroquine Drug Tests 
Drug tests were conducted using the microtechnique and a range of 
doses comparable to those used by Rieckmann et al. (1978); These doses 
were found to be too low to significantly affect the development of the 
parasites. A higher range of doses (1.25 - 10 jig per well) was more 
effective (Table 27). 	Cultures were set up in the morning (10.00 hours) 
when the parasites were at an early trophozoite stage with parasitaemias 
of not greater than 5%. 	The cultures were harvested when ring forms 
were predominantly visible in vivo, following schizogony; in vivo 
schizogony occured around midnight or early morning. 	The parasite 
maturation in vitro was slower than that observed in vivo (Table 27). 
Schizonts were not visible in the peripheral blood so that evidence for 
schizogony in vivo was the presence of the ring forms accompanied by an 
increase in parasitaemia. 
From the results it can be seen that morphological differences were 
apparent between the AS(30CQ) and the AJ(Sens) lines. 	The undrugged 
controls formed schizonts around midnight. 	At .a dose of 1.2511g the 
TABLE 26. Experiment 4 - Competition Studies Between Blood 
Forms of AJ(30C) and AS(30CQ) Lines 
Passage No, 
LDH 
RUN I RUN II RUN III 
1 2=3 23 
3 2=3 2=3 
9 2>3 2>>3 2>>3 
11 2>3 2>)3 
12 2>3 2>>3 2>)3 
SEE TABLE 22 FOR KEY. 
I, II, III - Replicate gel runs on the same samples. 
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TABLE 27. 	Effects of Chloroquine on Two Lines of P. chabaudi 
Time Examined 
No. of hours from start 
of culture 
SENSITIVE LINE - AJ(Sens) 
In vivo 
In vitro 







RESISTANT LINE - AS30CQ 
In vivo 
In vitro 





















Trophozoites with vacuoles 














Trophozoites with vacuoles 












Trophozoites with vacuoles 












- sensitive parasites formed schizonts but to a lesser extent than the 
undrugged parasites. 	Furthermore, the schizonts formed in the presence 
of the drug appeared abnormal. At the same dose, the resistant line be-
came arrested in its development at a vacuolated trophozoite stage 
which at times gave the parasites a foamy appearance. 	In the presence 
of a higher dose of 2.5 .ig the sensitive parasites developed as they 
did at 1.25 .ig, however, they seemed to be delayed in their development 
and do not form schizonts. 	The resistant parasites gave the same res- 
ponse at this dose as the dose of 1.25 pg. 	At higher doses, the sensi- 
tive parasites were eliminated whilst those of the resistant line were 
retarded; they seemed to contract to form rings. 	The cultures were 
examined later and it was found that the undrugged parasites continued 
to develop to form rings which reinvaded blood cells. 
The contents of the wells were inoculated into clean mice after 
the drug tests. 	The infections resulting from the inoculation of the 
cultures revealed differences in the viability of the parasites (Table 
28). 	The resistant parasites were more viable than the sensitive forms 
following drug treatment. 
3.8 Selection of Mefloquine-Resistance 
It has been previously shown that 10 mg kg- 
1 
 mefloquine eradicates 
different lines of P. chabaudi (see Section 3.4.1) , and that a graded 
response is obtained with 7 mg kg- 
1  of the drug depending on the line 
used (see Table 9 in Section 3.4.1). 	The three lines used for selection 
were AS(OCQ) , AS(3CQ) and AS(15CQ) (Table 1). 	Attempts to establish 
resistance in AS(OCQ) and AS(3CQ) lines were unsuccessful (Table 29). 
The AS(15CQ) line responded to a gradual increase in drug pressure until 
a line resistant to 30 mg kg- 
1 
 mefloquine was obtained (Fig: 8). During 
TALE 28. Parasitaemias in Mice Inoculated from Cultures 
Chioroquine Dose 
In Culture 
(jig per well) 
% Parasitaemia 
Sensitive Line Resistant Line 
D6 D4 
0 3.9 	 20 1,0 	 22 
1.25 -. 	 - 0.1 	 2.7 
2.5 - 	 - 0.06 	2.3 
5.0 - 	 - - 	 0.03 
10,0 - 	 - - 	 - 
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TABLE 29. 	Selection for Mefloquine Resistance in AS(OCQ) 
and AS(3CQ) Lines 
AS (OCQ) AS (30Q) 
Passage DOSE 
DAY OF INFECTION DOSE DAY OF INFECTION 
No. (mg kg1) showing a posit- (mg kg- I showing a posit- ive response. ive response 
1 7 - 5 D4 
2 5 D6 8 D6 
3 8 D8 8 
D 14 
4 8 D12 8 
D 11 
5 8 D5 10 - 
6 10 - 10 - 
7 10 - 
- : Denotes a negative response up to D15. 
DO 
81. 
the selection procedure the parasites were transmitted through mosquitoes 
as shown to generate the lines AS(12MF) and AS(15MF). 
3.9 	Response of Selected Lines to Chloroquine 
3.9,1 	Response of AS(12MF) Line 
The AS(12MF) line was tested with 15 and 30 mg kg- 1 chioroquine; 
at these doses the mefloquine-resistant line appeared to demonstrate a 
level of resistance equal to the AS(2OQ) line (Tables 4 & 30). 	As the 
parasites produced patent parasitaemias at D 11 following treatment of 
30 mg kg ' chloroquine, by definition (see Section 3.2.4) this line can 
be considered as resistant to chloroquine at a high level (300Q). 
3.9.2 	Response of AS(30MF) Line 
The AS(30MF) line was tested at various doses of chloroquine from 
5 - 30 mg kg 1 . 	The level of resistance of this line seemed to be in- 
creased from 15cQ to 20X (Table 4). 	By definition this line can also 
be classified as a 30cQ line (see Section 3.2,4). 
3.10 Stability of Resistance of Selected Lines 
3.10.1 	Response of AS(12MF) Line 
The resistance of this line was stable after mosquito transmission 
when tested with 10 mg kg- 
1 
 mefloquine for 4 days (Table 30). 
3.10.2 	Response of AS(301,TF) Line 
On multiple blood passage, this line seemed to be only moderately 
stable, emerging progressively later after drug treatment (Table 31). 
During the course of selection, this line proved to have reduced infect-
ivity to mosquitoes, probably as a result of multiple blood passage. 
However, after several attempts the line was eventually transmitted. 
TABLE 30. 	Comparison Between AS(12MF), AS(3CQ) and AS(3O(X) Lines 
% Parasitaemia(± S.E. 
DRUG TREATMENT 
(mg kg-1/days) 1OMF/4 150Q/6 300Q/6 
DAY OF INFECTION 1)9 	D11 	D13 D 
15 
D9 	DI , 	
D13 	D15 1)9 	Dll 
 
D13 	D15 	UND D9 
AS(3CQ) - 	- 	- - - 	- 	- 	- - 	- - 	- 	PP 
AS(30CQ) - 	- 	- - 0.13 	1.44 	2.63 - 	0.13 2.35 	 PP 
± ± ± ± ± 
(0.09) 	(0.75) 	(0.61) (0.09) (1.2) 
AS(12MF) - 	0.003 	0.4 4.1 - 	0.16 	2.8 - 	0.03 0.47 	 PP 
± ± ± ± ± ± ± 
(0.003)(0.18) (2.3) (0.09) 	(1.1) (0) (0.03) 
Drugged Animals - mean of 3 mice, 
UND : Undrugged animals - mean of 2 mice. 
PP : Post Peak. 
00 
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TABLE 31. 	Stability of AS(30MF) Before Mosquito Transmission 
% Parasitaeinja(± SE.) on first 
day of Positive Infection. 
Drug Dose 






0.01(±0.005) D10 0.015(±0.009) 
16 D14 
	0.35(±0.23) D19 	2.1(±2.1) 
LEGEND AS FOR FIGURE 13. 
Drugged Animals - mean of 3 mice. 
Undrugged animals - all post peak infections on D 9 
30 	controls negative in all tests. 
Fig.13 Stability of the AS(30MF) Line 

















SENSITIVE* 	SENSITIVE* 	 RESISTANTt 
CLONED FROM 
DRUGGED ANIMAL 
* Sensitive to 15mg kg 1 MF for 4 days 
t Resistant to 15 mg kg 1 MF for 4 days 
I Resistant to 30 mg kg -1 MF for 4 days 







Following transmission, this line demonstrated a lower level of 
inefloquine-resistance (AS (15MF)) (Fig. 13 and Tables .39 & 40, in Appendix). 
After a second mosquito transmission, the resistance was lost (Fig. 13 
and Table 40 in Appendix). 	The AS(15MF) line had a variable stability 
on multiple blood passage in the absence of the drug; following one 
mosquito transmission (d.f. no.870) it appeared to be unstable (Fig. 13 
and Table 41 in Appendix) and after another separate transmission (d.f. 
no.900) it was stable (Fig. 13 and Tables 32 & 41 in Appendix). 	The 
parasites which survived the drug test on passage no. 16 were cloned. 
A single clone was obtained after inoculating 50 mice. 	This line 
seemed to be stable after 8 blood passages without drug pressure and 
emerged earlier following drug treatment than the uncloned population 
(Table 32). 	The stability of this clone on further blood passage is yet 
to be determined. 	Two unsuccessful attempts were made to transmit this 
clone through mosquitoes. 
3.11 	Cross-Resistance to Quinine 
As mefloquine and quinine are structurally similar, the possibility 
of cross-resistance between the two drugs was investigated. Two lines 
were tested; these were: 
AS(30MF) before mosquitoes. 
AS(15MF). This line was the AS(3OMF) line transmitted through 
mosquitoes. 
The AS(15CQ) line was used as a control. 	The mefloquine-resistant lines 
were found to be cross-resistant to quinine (Table 33) . 	However, the 
degree of cross-resistance in AS(15MF) parasites did not appear to differ 
significantly from that of chloroquine as the AS(150) control values were 
as high as those of the AS (1511F) line. 	The AS(3OMF) values were moder- 
ately higher than the control values. 
TABLE 32: Stability of the AS(15MF) Line 
% Parasitaemia(± S.E.) 
Day of Infection D6 	D8 	D10 	D12 	D13 	D14 	D15 
PASSAGE NO. after AS(15MF) 
POPULATION Mosquitoes 
2 - 	 - 	 - 	 - 	 - 	 0,12(±0.06) 
6 - 	 - 	 - 	 - 	 O08(±0.025) 
16 - 	 - 	 - 	 - 	 0.015(±0.009) 
AS(15MF) PASSAGE NO. after 
CLONE DRUG TREATMENT 
8 - 	 0.04 	0.3 
(±O.) (±0 . 1) 
Drugged animals - Mean of 3 mice, treated with 15 mg kg 1 MF for 4 days 
Undrugged animals - POST PEAK on D10 
AS(30CQ) controls negative in all tests 
Legend as for Figure 13 
00 
U' 
TABLE 33. Response of Mefloguine-Resistant Lines to Quinine 
% Parasitaemia(± S.E.) 
DOSE (Mg Kg 1 
150 200 250 
for 4 days)  
Day of Infection D6 	D8 D10 UND D6 D6 	D8 	D10 UND D6 D6 D8 	D10 UND D6 
9.3 	23.0 32.0 0.06 	5..2 	25 13 0.03 0.9 	5.8 14.0 
AS(30MF) 
(±1 . 2)(±2 . 9 ) 
PP 
(±5 . 0) (±0 . 04)(±4 . 2 ) 	(±10 . 4)(±10 . 0 ) (±0 . 3 ) (±0 . 5 ) 	±1.5 (±11 . 3 ) 
AS(15MF) POPULATION 
0.12 	1.5 3.1 22.0 0.9 	8.8 20(+0) - 
0.11 13.3 
(±0 . 07)(±0 . 6) (±0.2) (j14.1) - (±0 . 6) 	(±4 . 2) (±°.°) 
0.8 	12 38 0.13 	5.6 30 0.007 0.61 14.8 
AS(15CQ) CONTROL ±°.) 	(±6 . 3 ) 
PP 
(±2.0) - 	 (±0 . 07)(±3 . 6 ) (±8 . 1 ) (±0 . 009)(±0 . 4 ) (±5 . 2 ) 
Drugged animals, mean of 3 mice 





4.1 General Mechanisms of Drug Resistance 
The development of resistance of malaria parasites to chemotherapy 
is a growing problem. The study of different types of mechanisms in-
volved in the emergence of drug resistance would lead to better evalua- 
tions of the use of the present drugs available. 	There are several 
theoretical ways in which drug resistance can occur. 	These include: 
Adaptive mechanisms. 	Hinshelwood (1946) called this a theory of 
direct induction in bacterial systems. Here, the organism has the 
ability to switch on alternative pathways to thosewhich may have been 
blocked. 	These physiological changes are non-genetic, are likely to 
be unstable and would only be induced in the presence of the drug. 
Selection of existing resistant forms under drug pressure from 
mixed populations of sensitive and resistant parasites. 	The difficulty 
with this mechanism is that it does not account satisfactorily for the 
different levels of resistance observed; It would have to postulate the 
pre-existence of several different resistant parasites. 	It also does 
not account for the specificity of some of the drug resistance characters. 
Spontaneous mutation of nuclear genes followed by selection and sub-
sequent multiplication of mutants. 	This is the most likely mechanism 
which is operating in Plasmodia. Here, a permanent change occurs which 
can recombine autonomously with other characters (for example, pyri-
methamine -resistance in P. gallinaceum developed by Bishop, 1958; pyri-
methaniine-resistance in P. yoelii by Morgan, 1974 and in P. chabaudI by 
MacLeod, 1977). 
88. 
Spontaneous mutations of extranuclear (for example, niitochondrial) 
genes followed by selection (see review by Jinks, 1964). 	Examples of 
extrachromosomal inheritance in Protczoa are provided by Beale & Knowles 
(1978) in P. aurelia where drug resistance could only be 
accounted for by such a mechanism; Sager (1954) in alga, Chlamydomonas 
reinhardi, where streptomycin-resistance was shown to develop by typical 
Mendelian and extrachromosoinal mutations. 
Gene mutation induced by mutagens. 	These would be non-specific. 
For example, in the selection for pyrirneth amine -resistance (Morgan, 1974) 
UV was used to induce a greater number of mutations; a mutation con-
fering an increase in virulence was obtained. 	However, there is no 
evidence of mutagens inducing specific mutations to drug resistance in 
Plasmodia. 	In the work of Morgan (1974) the drug itself probably 
selected for the emergence of pyriinethamine-resistance. 
Switches in gene expression caused by changes in cytoplasmic or 
environmental factors (for example, altered membrane structure and 
permeability). 
Transfer of drug resistance factors in plasmids from one cell to 
another such as those found in bacterial systems (see reviews by 
Demerec, 1957; Watanabe, 1963; Watanabe & Fukasawa, 1966; Hayes, 
1967). 	So far there is no evidence for parallel mechanisms of R 
(resistance) factors in Plasmodia although transformation of pararosaniline 
resistance has been claimed in another parasite Trypanosoma garbiense 
in vitro (Inoki & Matsushiro, 1960); virus particles have also been 
observed in Plasmodia (Terzakis, 1969). 	Nonetheless, there is still 
no convincing evidence of this type of gene transfer in Plasmodia. A 
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mechanism of transfer of drug resistance cytoplasmically, called 
synpholia, has been proposed by Yoeli et al. (1969). 	This is discussed 
elsewhere (see Section 4,5). 
(8) A mechanism was proposed by Yudkin (1953) called the theory of 
clonal variation. 	This theory tries to account for features character- 
istic of bacterial drug resistance which are also observed in Plasmodia. 
These are: 
The training of organisms to grow in otherwise lethal concentrations 
of the drug, 
Reversion of resistance to sensitivity in the absence of the drug. 
The basis of this theory is that a resistant bacterial cell may give rise 
to 2 cells with different and unequal degrees of resistance. 	Under 
gradually increasing drug pressure a continuous selection of daughter 
cells with high levels of resistance will occur. 	This resistance can 
arise without any need for conventional genetic mutation. 	However, 
there is no evidence for this mechanism from malaria studies. 	As 
Pollock (1960) pointed out, selection pressure at a given drug concent-
ration would not necessarily favour a highly resistant gene combination 
when a less resistant mutantwould grow as well. 	This theory does not 
explain cases of high mutation rates when a high level of resistance is 
obtained very rapidly such as with pyrimethanine-resistance in Plasmodia. 
The likely mechanisms involved in Plasmodia are discussed by 
Schnitzer and Grunberg (1957) where the authors stress the genetic 
origins of drug resistance. 	The development of drug resistance in P. 
chabaudi is likely to have a genetic mutational basis. 	Adaptive 
mechanisms may also be in operation which would account for the unstable 
types of resistance reported in the literature (see Introduction). The 
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development of chioroquine- and mefloquine-resistance are discussed in 
relation to these mechanisms. 
4.2 	Variation Due to Host Effects 
The results of the drug tests used in this investigation were 
highly variable. 	Variation occured from one drug test to another both 
within lines and between supposedly parallel lines. 	The most important 
factor responsible for this variation is that of the response in experi- 
mental animals. 	It has been found that mice of the C57 inbred strain, 
which was the strain used in the drug tests of this investigation, 
were more variable in their response to the drug nembutal than F 1 
hybrids from crosses between two inbred lines (McLaren & MichieI, 1956; 
Biggers et al., 1958; Falconer, 1960). 	The rate at which a drug is 
concentrated and maintained in red blood cells depends on the host 
which controls the absorption of drugs from the alimentary tract 
(Vessel et al., 1971). 	The sex and age of the host may be contributary 
factors to the variation in drug response observed during drug tests. 
Work carried out by Konopkaetal. (1966) on P. berghei suggests that 
female rodents were less protected by quinine than males, although the 
opposite effect was found with other drugs. Other workers have found 
that although female and male rats were equally susceptible to P. berghei 
infections, females had more effective natural immunity than males 
(Zuckerman & Yoeli, 1954). 	It is also thought that the route of in- 
fection would also be important in initiating uniform infections; the 
intravenous route is thought to be more reliable than the intraperitoneal 
route (Ott, 1969; Weildeetal., 1966). 
During the drug tests undertaken in this investigation, only young 
female C57 mice were used throughout to eliminate variation due to sex. 
91. 
The animals were weighed individually in the chioroquine drug tests 
to determine the exact amount of drug required for each mouse so that 
the same concentration of drug was administered to each mouse. Mean 
weights of mice were taken for other drug tests. As it would take a 
comparatively long time to inoculate each animal intravenously which 
would then complicate the exact interval between inoculation and ad-
ministration of the drug for each mouse, the infections were started 
int rape ritoneally. 
As seen from the results of the drug tests, in spite of the pre-
cautions taken, the results were still variable. 	Standard errors of 
over 50% were common (For example, Table 4). 	However, the most 
reliable criterion for determining whether parasites were resistant was 
either presence or absence of healthy parasites after drug treatment, 
rather than the actual levels of parasitaemias. 
The time of schizogony was also variable. This had particular 
relevance to in vitro drug tests where the infections were monitored 
in the donor mice to determine at what time parasites should be examined 
from cultures. 	Although mice were standardized for age and weight, 
the time of schizogony varied by about 2 hours from day to day and by 
as much as 8 hours from one season to another according to the natural 
light/dark cycle. 	Thus, the conditions of the host affected the time 
at which parasites underwent schizogony, 
4.3 Chloroquine-Resistance in Line AS 
The method with which chloroquine- resistance was developed in AS 
can lead to some deductions of the genetic events which may have occured. 
As the parasites only responded to a selection programme which involved 
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a gradual increase in drug pressure it would seem that several steps 
or mutations may have been involved in the development of the highly 
resistant line AS (300Q) 	These mutations may be discrete changes at 
several loci which have an additive effect or may be a series of 
mutations at one locus. 	It was-shown that the highly resistant line 
was stable through several blood passages and mosquito transmissions 
(Fig. 11). 	On cloning, the line remained highly resistant. 	It 
would seem, therefore, that a stable and permanent change or changes 
had occured in the development of this line. 
The chloroquine tests carried out during selection provide evi-
dence of different levels of resistance. 	The drug tests with varying 
doses of chloroquine suggest that there are at least four classes of 
resistant parasites (Table 4), 	The drug delay experiments reveal 
differences between the AS(3CQ), AS(15cQ) and AS(30cQ) lines (Figs. 9 
& 10). 	The data on cross-resistance between chloroquine and the 
drugs mefloquine, mepacrine and quinine also imply that there are 
different levels o±chloroquine-resistance (Fig. 12a,Tables 9, 10 & 11). 
Cross-resistance of chloroquine-resistant strains to these drugs and 
other 4-amino quinolines has been reviewed by Peters (1970). 	This 
author also pointed out (1967) that cross-resistance between different 
compounds may not be an all-or-nothing phenomenon but dependent on the 
level of resistance in each case (Greenberg & Bond, 1954 with pyri-
methamine- resistance in P, gllinaceum; Contacos et al., 1963. with 
multiple resistance in P. falciparum in the Far East). The data on 
cross-resistance between chloroquine and mefloquine indicates that 
there are different classes of chloroquine-resistance although the 
exact number of classes is unclear (Fig. 120, The drug tests with 
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mepacrine clearly show differences between the low and high levels 
of resistance (Table 10). 	The results with quinine are less striking; 
they show differences between the sensitive and resistant lines (Table 
11). 	It can be seen that very high doses of quinine are needed for 
the tests and the highest dose of 250 mg kg- 
I 
 is already higher than 
the reported maximum tolerated dose of the mouse which is 150 mg kg- I 
(Hawking, 1966). 	The significance of the results obtained with the 
mefloquine-resistant line will be discussed elsewhere (see Section 4.8). 
If there are indeed different levels of chioroquine-resistance and 
the evidence presented here supports this view, this provides additional 
evidence that several steps are involved in the acquisition of the 
AS (30Q) line, 
4.4 Genetic Analyses 
The results of the genetic crosses confirm that the AS(30X) line 
is due to several mutations, as parasites with intermediate levels of 
resistance were observed among the progeny. The exact number of 
mutations is unclear. 	Although three levels of chioroquine-resistance 
were classified there may well be more levels than this between 3 and 
30C; the drug test may not have been sensitive enough to distinguish 
between them. 	For the purposes of this investigation, the resistance 
of the progeny clones was classified according to the rate at which 
the parasites emerged after drug treatment. 	The-test used to classify 
the clones allowed for a range of different levels of resistance. 
Parasites were grouped into the 15CQ category if they emerged by D 13 
or D15 , and into the 30CQ class when they emerged by D 9 or D11 , following 
a drug test of 30 mg kg- 
1 
 chioroquine for 6 days. 	Thus, within these 
groups there is a range of rates of growth. 	These classifications may 
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indeed be artificial and chloroquine-resistance may be phenotypically 
a continuous variable character. 
The question of whether discrete mutations at different loci were 
involved in the expression of the 30Q resistance could be resolved 
by conducting a cross between a 30CQ and a 30Q line. Should sensitive 
parasites emerge, then clearly the mutations are at different loci. 
However, should only a range of different levels of chloroquine re-
sistance arise, then this phenomenon may be due to several mutations 
at a single locus. 	All these arguments are based on the assumption 
that chloroquine-resistance per se is genetically inherited and due 
to mutations of nuclear genes. 	The evidence from the crosses here and 
from previous work (Rosario, 1976a,b) suggest that this assumption is 
most probable as the character recombines independently of other markers. 
In addition, intermediate levels of resistance can only be obtained 
after conducting a cross. 	Competition experiments (see Section 4.4.5) 
imply that cytoplasmic inheritance is not operating in this case. 
On conducting a cross, assuming random mating and no selection 
confering advantage on a particular character, theoretically the numbers 
of each class should be equal (Fig. 5). 	There is a preponderance of 
parental types due to self-fertilization. 	This clearly has not 
happened in the crosses conducted; several anomalies appeared. 
4.4.1 	Cross 1 
The results of the drug tests on the uncloned progeny of the 
Crosses 1 and 2, and the electrophoresis data, indicated that both 
parental and recombinant types were present (Fig. 12). 	However, 
in Cross 1 in which the AS(300Q) line was crossed with the AJ(Sens 
line, there was clearly an excess of the AJ parental type in the un-
selected progeny of the cross (Table 13). 	This phenomenon was also 
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observed by Rosario (1976a,b), where following a cross between the 
AS(3) and AJ(Sens) lines, he obtained 32 parental AJ(Sens) clones 
from a total of 70 clones compared with 4 parental AS(3CQ) clones. 
In this work, Cross 1 yielded 10 chioroquine-resistant clones in a 
total of 33 clones in the unselected progeny of the cross (Table 13); 
on investigating the level of.chloroquine-resistance in greater detail 
there was an absence of the high level of resistance (Table 18). 
This is unexpected as a quarter of the total progeny of the mating 
should have yielded parental highly resistant parasites due to selfing 
(Fig. 5). From the numbers of oocysts found in mosquitoes infected 
with each line separately (Control cages), both lines were apparently 
equally fertile. 
After the progeny were selected using different levels of the 
drug, from a total of 27 highly resistant clones, only one was of the 
AS(300Q) parental type. 	All of the clones established after selection 
at 30 mg kg- 1 had AJ enzyme types and were therefore recombinant. It 
is possible that the results were due to chance and that on cloning 
most of the clones were derived from one class of parasites; as the 
cloning procedure requires low n&2uIo 	 ' a more virulent 
parasite would stand a better chance of being selected. 	However, of 
the 97 clones established from Cross 1, 64 were obtained after drug 
treatment which would favour the emergence of resistant and hence AS 
parental types. 	There is strong evidence, therefore, that the AS(30CQ) 
parental types are at a selective disadvantage. 
- 	
Table 19 summarizes the 
enzyme types of the cloned progeny of the cross; it can be seen that 
the AJ enzyme types are predominant. 	The significance of this will be 
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discussed elsewhere (see Section 4.5). 
4.4.2 	Cross 2 
In Cross 1, clones exhibiting high levels of chloroquine-resistance 
could only be obtained by selection (Table 18). 	It is possible that 
if more clones had been obtained without selection, some clones with a 
high level of resistance would have been found. However, even after 
selection only one clone from a total of 60 resistant clones was of the 
AS(30CQ) parental type. 	Cross 2 which is a repetition of Cross 1, was 
therefore conducted to determine whether the results- obtained in Cross 
1 were unique to the cross or typical of such a cross. 	21 clones 
were established from the cloned progeny of this cross. 	In this cross 
the enzyme markers seemed to be segregating equally (Table 21) as ex- 
pected of Mendelian genetics. 	The chioroquine response of the clones 
indicate that a variety of sensitive and resistant forms were obtained. 
Although in this cross highly resistant 30CQ clones were obtained, 
unfortunately all of the clones were pyrimethainine-sensitive, and 
therefore the chloroquine-resistant clones were recombinants; so again, 
no highly resistant parental types were obtained. 
Clearly, several factors are influencing the results of the crosses 
conducted. 	Because of the anomalous frequencies of parental types, 
an accurate assessment of recombination frequencies of the markers used 
was not possible. 	Ideally, the method of hybridization employed 
would be to fertilize isolated macrogainetes of one line with micro- 
gametes of the other. 	The resulting zygotes would then develop into 
oocysts from which sporozoites arise; single sporozoites should then 
be inoculated into-individual mice. 	This procedure is not yet 
technically feasible. 	Attempts to initiate infections from sporozoites 
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of single oocysts have been reported (Trembley et al. , 1951; Walliker, 
1972). 	Unfortunately, these efforts have been met with limited 
success and would be impractical for the large numbers required for 
genetic analyses. 
An improvement of the present method of conducting a cross which 
would confirm the genetic basis of drug resistance markers would be by 
making use of microgamete preparations. 	For example, if microgametes 
of the AS line with the drug resistance markers were prepared and mixed 
with micro- and macroga!netes of the AJ sensitive line, all the drug re- 
sistant parasites could only be products of cross-fertilization. 	In 
addition, this would confirm the nuclear inheritance of these markers 
as the structure of microgainetes 	mainly consists of nuclei withLaIrnost no 
cytoplasm. 	Attempts to develop this technique in this laboratory have 
been mainly unsuccessful (Brown, unpublished). 
A further refinement which would eliminate sampling errors and 
which would allow sampling at different stages of infection is by 
cloning using micromanipulation. 	This has been achieved with avian 
malaria parasites by Demidowa (1934), Coulston and Manwell (1941), 
Downs (1947) and Bishop (1958); and with rodent pars ites by Diggens 
(1970). 	Due to the large numbers of clones requiredin a short time, 
this method of cloning had not been adopted in genetic work. 
4.5 Reconstruction and Competition Experiments 
The object of these experiments was to determine whether the ab-
sence of certain progeny classes was due to their selective disadvantage 
compared with other forms. 	The results of the competition experiments 
indicate that the AJ(Sens) line appears to be at an advantage over the 
AS(Sens) line (Table 23). 	The recombinant AJ(300) line also seems to 
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be favoured over the AS(300Q) lines (Table 26). 	In competition the 
parents of Crosses 1 and 2 appear to be neutral (Table 25). 	However, 
these experiments were conducted using the electrophoresis system to 
monitor any differences which might arise. 	The data of reconstruction 
experiments indicate that the-system is not sensitive in detecting 
large differences; proportions of 70:30 and less are difficult to 
detect (Table 22). 
The highly chloroquine-resist ant (AS(30CQ)) character per se has 
been shown to be at an advantage over the parental sensitive AS(0Q) 
character (Table 24). 	A low level of resistance (AS(3cQ)) was also 
found by Rosario et al. (1978) to possess a selective advantage. 	In 
addition, there is the influences of the pyrimethamine-resistance marker. 
This marker has been shown to be at an apparent disadvantage compared 
with the 'wild type' sensitive forms (Rosario et al., 1978). 	If the 
pyrimethamine-sensitive forms are indeed at a selective advantage then 
it can be seen that as far as the drug resistance markers are concerned 
the selective forces would be acting in opposite directions in the 
competition experiment between the AS(30cQ) and the AJ(Sens) lines. 
This could account for the neutral results of the two lines when placed 
in competition with each other. 
However, the mechanism involved in the chioroquine-resistant para-
sites outgrowing the sensitive forms is unclear. 	It is thought that 
there is a reduction of virulence with chloroquine-resistance in P. 
berghei (Sergent & Poncet, 1959; Peters, 1964; Jacobs, 1965). 	It has 
been observed that there is a tendency for resistant parasites to invade 
immature cells in P. berghei (Peters, 1968b); the diminished virulence 
in chloroquine-resistant forms may be due to a delay before reticulo- 
cytes are formed and consequently, parasites which can only live in young 
erythrocytes may have to wait to invade the new cells. 	Chloroquine- 
resistant P. chabauth invades both immature and mature erythrocytes so 
that there is no reason for such a decrease in virulence of resistant 
forms. The competition experiments with chioroquine-resistant lines 
of this .species certainly suggest that the resistant parasites outgrow 
the sensitive forms (Table 24 & Rosario et al., 1978). 
The results of the competition experiments between the drug sensi-
tive AS and AJ lines, the AJ(3000,) and AS(30C) lines are striking 
(Tables 23 & 26). 	The fact that differences can be detected means 
that the proportional differences are probably greater than 70:30 
(Table 22). 	The apparent advantage of the AJ background could partly 
account for the results obtained both by Rosario (1976a,b) and the 
results of Cross 1 presented in this investigation. 	The apparent 
selective advantage of the recombinant AJ(30Q) line could be explained 
in terms of 'vigour'. 	As the parasites are haploid and the term 'hybrid' 
has been. mainly attributed to diploid organisms, this phenomenon should 
perhaps be referred to as 'recombinant vigour' in this case. 
Examining the enzyme types of the clones obtained from Cross 1 
reveal that 62 out of a total of 97 clones were of the AJ parntal 
type whilst only 27, were of the AS parental type (Table 19). 	In Cross 
2 the enzymes seem to segregate equally, however, all of the clones 
were recombinants (Table 21) apart from 5 of the clones which were of 
the parental AJ type. 	The majority of the clones were therefore re- 
coinbinants which seem to have a selective advantage certainly over the 
highly resistant parental type. 	Only a small number of clones were 
isolated from this cross; had more clones been obtained the AJ enzyme 
types may have been found in excess as they were in Cross 1 and the 
cross conducted by Rosario (1976a,b). 
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The influence of these various selective factors could also 
account for the apparent failure of the highly resistant parasites to 
outgrow the sensitive forms in the crosses (Table 12) ; the chloroquine-
resistant phenotype is expected to outgrow the sensitive forms if they 
are at a selective advantage. 
In Experiment 2 of the 
competition work (AS(30) vs AS(0Q)) only highly resistant or sensitive 
clones were established (Table 24) ; no intermediate levels of resistances 
were obtained. 	After drug treatment at a low level before cloning, 
only highly resistant clones were obtained (Table 24). 	In Experiment 
3 (AS(30cQ) vs AJ(Sens)), after drug treatment at a high level, only,  
the AS enzyme type was observed (Table 25). 	These results indicate 
that the sexual mosquito stages of the life cycle of the parasites is 
required for exchange of genetic material to occur resulting in para-
sites showing intermediate levels of resistance.- r 
This gives no support to the hypothesis of Yoeli et al. (1969) that 	- 
some form of genetic transferor infection might occur between different 
parasites in the same blood cell. 
- 	- 	 However, as mentioned 
in the Introduction (see Section 1.8.2) the results obtained by these 
authors have not been repeated subsequently. 
These results obtained here are interesting in the light of the 
variation found between species of malaria in man. 	The different 
levels of resistance developed in P. chabaudi may reflect the variation 
found in P. falciparum in man; RI, RII and lUll levels of chloroquine- 
resistance have been observed (WHO, 1973). 	These varying levels of 
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resistance in P. falciparum may have arisen by a slow increase of 
resistance due to the continued use of the drug as a prophylactic over 
a long period of time. 
The competition experiments suggest that there is natural vari-
ation withinspecies 	 - 
The difference between AS(Sens) and AJ(Sens) may be in rates of growth, 
and such differences may exist in other species also. 
-- 	 The idea of cross products being more 'vigorous' and 
hence more of a threat than parental lines is alarming. 	In addition 
to the apparent selective advantage of the chloroquine- resistance 
character the increased growth rate of the cross products would compound 
the selection in favour of any chloroquine-resistant parasites arising 
from the cross. Both of these factors may have been contributary to 
the increase in numbers of chioroquine-resistant P. falciparum parasites. 
Furthermore, as the selective advantage of the resistant forms continues 
to persist in the absence of the drug, this would account for resistant 
parasites beingmaintained in the population even in areas where the 
drug has been discontinued. 
4.6 	In vitro Drug Tests 
In vitro drug tests were attempted in order to standarize the drug 
test by eliminating host effects. 	It was hoped that these tests would 
provide a more accurate method of testing parasites for chloroquine 
et al. 
response. 	In P. falciparum, Rieckmann/(1978) found that following in 
vitro culture, parasites of a chloroquine- resistant line formed schizonts 
in the presence of the drug whereas sensitive parasites did not. This 
was not observed with the P. chabaudi lines examined here. 	In the ab- 
sence of the drug, parasites matured to schizonts (Table 27). 	Much 
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higher doses of the drug than those used by Rieckmann et al. (1978) 
were required for antimalarial activity against P. chabaudi in vitro. 
In the presence of the drug a morphological difference was observed 
between the two lines.. 	At low doses of chloroquine (1.2 & 2.5 Pg) the 
sensitive line had a delayed development; the parasites formed 
schizonts much later than the undrugged controls. Nevertheless, the 
sensitive parasites continued to develop, forming parasites with abnormal 
appearance. 	With the resistant line, low doses of chloroquine initiated 
vacuole formation and the development of the parasite appeared to be 
arrested at the trophozoite stage, these trophozoites contained vacuoles. 
At higher doses of the drug (5.0 & 10.0 jig), the sensitive line 
generally did not survive whereas the resistant forms were retarded to 
produce rings. 
Inoculations from the cultures into clean mice reveal that the 
sensitive line is less viable after drug treatment than the resistant 
line (Table 28). 	The resistant parasites survive the dose of 5 pg 
whereas the sensitive parasites did not survive a dose of 5 pg. 	The 
in vitro drug tests thus revealed morphological differences between the 
AJ(Sens) and the AS(300) lines. 	However, this observation is qualit- 
ative and the test did not yield quantitative results. 	This method 
was, therefore, not adopted as a drug test to distinguish between differ-
ent levels of resistance. 	Although the inoculations from the cultures 
demonstrated variation in the viability of the two lines it is doubt-
ful whether this test would be sensitive enough to show the differences 
between the chloroquine-resistant lines. However, the morphological 
differences between the lines were of considerable interest because pig-
ment clumping and vacuolation in association with chioroquine-resistance 
has been found by various workers (see Section 1.6 and Peters et al., 
1965; Peters. and Fletcher, 1966; Rabinovich, 1968). 
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4.7 	Mefloquine-Resis tan cé 
One of the reasons for developing a new antimalarial drug is 
because of the emergence of multiply resistant human malaria parasites. 
It is therefore important to examine the potential of parasites to 
develop resistance to the new drug xnefloquine. 	By studying the patterns 
in which mefloquine-resistance arises, as with any other drug, means of 
minimising or preventing the development of drug resistance might be re- 
vealed. 	As the mode of action of mefloquine is not known, if resistance 
to the drug does arise the mechanisms involved can at this stage only 
be speculative. 
There is evidence that higher doses of mefloquine are needed to 
kii.i chloroquine-resistant strains than sensitive strains of P. falciparum. 
This has been shown in Aotus monkeys (Schmidt, 1973) and in man 
(Trenholme et al.,, 1975). 	It has also been found that in P. berghei 
mefloquine is less active against chloroquine-resistant strains compared 
with drug sensitive strains ( Peters et al., 1977a). 
Unstable inefloquine-resistance has been established by the latter 
authors in P. berghei (Peters et al., 1977b). 	In this investigation 
attempts to establish mefloquine-resistance in P. chabaudi have been 
undertaken. 
In view of the decrease of activity against chloroquine-resistant 
lines of P. berghei it was not unexpected to find that xnefloquine was 
cross-resistant to chioroquine to a limited extent (Fig. 124 	It was 
also relatively easy to develop mefloquine-resistance in a line already 
resistant to a high level of chloroquine (15Q) than in lines which 
were either resistant to a low level of chloroquine (3X) or sensitive 
to this drug (Fig. S & Table 29). 	The level of chloroquine-resistaflce 
was raised marginally in the development of inefloquine-resistance which 
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confirms that the two drugs are in some way cross-resistant (Tables 
4 & 30). 
As with chioroquine, the strategy used for the development of 
mefloquine-resistance was a gradual increase in drug pressure. 
Mefloquine-resistance could not be obtained in a single step using the 
high pressure method of selection (Walliker, unptblished). 	This 
method involves inoculating a large number of mice and treating them 
with a high dose of the drug. 	Any parasites which survived this 
treatment are assumed to carry mutations for drug resistance. 	This 
strategy was highly successful in the selection for pyrimethamine-
resistance (Morgan, 1974; MacLeod, 1977). 
The mefloquine-resistant line developed was resistant to 30 mg kg 1 
mefloquine for 4 days. 	This line appeared to be moderately stable on 
multiple blood passage in the absence of the drug (Table 31), although 
the parasites survived the drug treatment it took progressively longer 
for the parasites to emerge. 	This line proved to be unstable on 
mosquito transmission (Fig. 13). On transmitting the line through 
mosquitoes once, the level of resistance was reduced to 15 mg kg
- 1 
in one case this resistance seemed to be unstable on multiple blood 
passage (Fig. 13 & Table 41 in appendix). On another occasion, the 
resistance seemed to be stable (Tables 32 & 41, in appendix). On 
transmitting this line a second time, the parasites appeared to be 
sensitive (Fig. 13 & Table 40, in appendix). It must be stressed 
that the mefloquine-resistant line was uncloned at this stage. 
Although the mefloquine-resistant line (AS(30MF)) appeared to be 
losing its resistance on multiple blood passage without drug pressure 
(Table 31), on cloning the resistant line after mosquito transmission 
(AS(15MF)), the resistance appeared to be stable and the parasites 
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emerged earlier than the original uncloned parasites after drug treat-
ment (Table 32). 	As this clone was derived from parasites surviving 
a drug test it could be presumed that any lower levels of resistance 
or unstable resistant parasites would have been screened out. 	The 
presence of such unstable resistant parasites or lower levels of re-
sistance could account for the delayed emergence of the parasites 
following .a drug test of the uncloned mefloquine-resistant line and the 
loss of resistance following a second mosquito transmission. 
Prior to cloning, the mefloquine-resistant AS(15MF) line had 
undergone 15 blood passages and had maintained its resistance to the 
drug. 	It is unlikely that a single drug test would have given rise 
to a stable mutation conferring resistance as the theIhod with which 
mefloquine-resistance was developed involved a gradual increase of drug 
pressure (Fig. 8), and that mefloquine-resistance could not be obtained 
in a single step (Walliker, unpublished). 	Therefore the clone ob- 
tained from the parasites surviving a single drug test on Passage 15, 
was likely to have already been resistant to the drug and its apparent 
increased survival following a drug test compared with the uncloned 
population, may have been due to the "purification" of the parasites. 
Clearly, more work is needed to fully characterize this clone. The 
clone should be transmitted through mosquitoes, although previous 
attempts to do so have failed, probably due to the reduced infectivity 
to mosquitoes of the parasites following multiple blood passages. The 
stability of this line should be investigated further. 	Once this line 
has been fully characterized it would be important to investigate the 
basis of this resistance using genetic techniques. 
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4.8 	Cross Resistance to Quinine 
Mefloquine is structurally similar to quinine. 	So far there is 
no widespread quinine-resistance. 	There are some reports of quinine- 
resistance in P. falciparum (McNamara et al., 1967; Clyde et al., 
1970). 	Glow et al. (1978) have selected for quinine-resistance in 
P. falciparum in Aotus monkeys by serial passage under repeated drug 
pressure. 	Therefore, clearly P. falciparum has the ability to develop 
resistance to this drug. 	However, to date, quinine is still active 
against most strains of P. falciparum including chloroquine- resistant 
Hall et al., 1976b,c) 
parasites (Smithurst, 1971/, although there are reports that increas- 
ingly higher doses are required for radical cure (Harinasutaetal.,, 
1965) and one Vietnamese (Smith) strain is relatively resistant to 
quinine (Clyde et al., 1970). 	However, Thai patients from Central 
Thailand were found to respond readily to quinine (Colwell et al., 1972). 
In spite of the doubts as to the reliability of quinine as an emergency 
measure when other drugs fail, it is still one of the few drugs 
available where resistance is not widespread, 	However it is possible 
that by the development of mefloquine-resistance the development of 
resistance to quinine could be accelerated. 
The mefloquine-resistant line established here was tested for its 
cross-resistance to quinine. 	Although at this stage the mefloquine- 
resistant line was not fully characterized there is evidence that the 
uncloned mefloquine-resistant line, AS(30MF) , is cross-resistant to 
quinine (Table 33). 	It would also be of value to know if the cloned 
mefloquine-resistant line (AS(15MF)), also demonstrated cross-resistance 
to quinine. 
Mefloquine seems to be a drug of great potential value for the 
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suppression or the treatment of chioroquine-resistant P. falciparuin. 
From this study it is clear that resistance to this drug can be readily 
developed. 	In addition, resistance to mefloquine may be a route to- 
wards the development of quinine-resistance,. 	Efforts should be made 
to evaluate how best to use this drug. 	It has been proposed by 
several authors that studies of combinatiorof mefloquine with other 
drugs, both to search for true potentiating properties and to find a 
safe combination with other antimalarials that will extend its useful 
life, should be undertaken (Peters et al., 1977b). 	Such drug combin- 
ation studies are already under way (Hall et al., 1977). 	Therefore, 
the continuing spread of drug resistance in malaria emphasises the 
need to use the existing antimalarial drugs wisely. 
4,9 	General Discussion 
The present study uses a genetic approach to investigate chioroquine-
and me floquine- resistance in the rodent malaria, P. chabaudi, Reports 
of unstable chloroquine- and inefloquine-resistance have already been 
laboratory-'induced 
reviewed (see Introduction). 	The first case of/stable chioroquine- 
resistance in rodent malaria was reported by Rosario (1976a,b). 	As 
mefloquine is a relatively recent drug, as yet, there are no reported 
cases of stable resistance to this drug. 	In this study a high level 
of chloroquine- resistance was selected in order to determine how many 
mutations are responsible for this high level of resistance. 	In 
addition, mefloquine was investigated to determine the feasibility of 
developing resistance to this drug. 
The highly resistant, AS(30CQ), line proved to be stable; this 
limpiles 	that permanent changes which presumably had a genetic basis 
had occured. 	The results of the crosses provided evidence for the 
I(sI:P 
multigenic nature of this chloroquine-resistance. 	The competition 
experiments provided support for the nuclear origins of the mutation 
involved as intermediate levels of resistance could only be obtained 
following a cross and not from blood mixtures. 	This is the first 
case where drug resistance in Plasmodia has been shown to be determined 
by more than one mutation. 
The possible mechanism by which chloroquine-resistance arises is 
still unclear. 	The theories so far put forward include the modifi- 
cation of clumping (Warhurst, 1973) and binding (Fitch, 1969) sites, 
These sites accumulate the drug; once inside the parasite, the drug 
probably intercalates with DNA and inhibits vital prOcesses such as 
RNA and protein synthesis. 	Mutations affecting clumping sites may be 
specific to chloroquine as they are structure specific (Warhurst & 
Thomas, 1975a), whereas mutations affecting binding sites may serve as 
the basis of cross-resistance observed between the 4-aminoquinolines 
and related drugs as the sites are not highly structure specific(Fitch, 1972 
Fitch et al., 1974c). 	If these mechanisms are correct, then it is 
likely that the high level of chloroquine-resistance may be due to 
several mutations of the genes coding for clumping and binding sites. 
These are likely to be discrete mutations at several loci as it 
would be unlikely that the same genes would code for both of the differ-
ent sites. 
Even if phenotypically chloroquine-resistance demonstrates con-
tinuous variation, at the gene level it may well be determined by 
several discrete genes at different loci which have additive effects 
confering a high level of resistance. 	The different classifications 
of levels of chloroquine-resistance in this investigation may be 
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arbitrary as it is based on the rate of emergence of the parasites 
after drug treatment; this criterion is not absolute and, as seen 
from the results, is subject to variation. 
The competition experiments reveal some unexpected consequences 
of the development of chloroquine-resistance. 	Previous work (Rosario, 
1976b; Rosario et al., 1978) and this present study has shown that not 
only do various lines differ in their selective advantage which may 
reflect the natural variability in wild populations, but that by 
changing their drug resistance properties, other features may be 
altered. The mutations to drug resistance may have pleiotropic 
effects, or in the course of selection for resistance, mutations 
altering growth patterns may have occurred. 
From studies with cross-resistance it is possible to evaluate how 
best to use the present antimalarial drugs. Previous work has shown 
that although pyrimethamine and chloroquine are drugs of different 
groups which do not demonstrate cross-resistance, it was easier to 
develop chioroquine-resistance on a pyrimethamine-resistant background 
than on a drug sensitive background (Powers, 1969; Rosario, 1976b). 
The basis of this phenomenon is unknown. 	It can be envisaged that in 
the course of selecting for pyriniethainine-resistance some general 
mechanism may have been altered, such as permeability of parasite mem-
branes, which would render the parasites inaccessible to other drugs; 
this could involve modifications of the binding sites (Fitch, 1969). 
This present study has shown that mefloquine and chioroquine demon-
strate a small degree of cross-resistance which may have facilitated 
the development of mefloquine-resistance. 	In addition, there are 
indications that inefloquine and quinine are cross-resistant. Although 
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the reliability of using quinine when other drugs fail is now in 
question, it is still one of the drugs left where resistance to it is 
not widespread. 	It would be unfortunate if by the development of 
inefloquine-resistance the development of quinine-resistance were accel-
erated. 
The extrapolation from this rodent model to the human malarias may 
be erroneous; however, the results with the rodent malaria system 
should give an indication of what to expect. 	With the development of 
in vitro culture systems (Trager & Jensen, 1976, 1977) 
the results obtained with murine malarias could either be confirmed or 
proved to be unique to rodents. 	Drug tests using in vitro culture 
systems of P. falciparum have already started using drug sensitive para- 
sites (Richards & Maples, 1979). 	Comparative studies between strains 
of P. falciparum from different areas are in progress in this laboratory. 
Artificially selected chioroquine-resistant lines of P. falciparum have 
also been established in vitro (Nguyen-Dinh & Trager, 1978). 	Thus, 
it is now possible to study the mechanisms of drug resistance directly 
on human malaria parasites. 
The application of molecular biological techniques to malarial 
systems is still in its infancy. 	Apart from its application in system- 
atics where species of rodent malaria have been demonstrated to differ 
in their buoyant density and hybridization properties (Chance et al., 
1978), little has been done in studying the molecular biology of 
Plasmodja. 	This approach should provide insights into the basic gene- 
tic organisation of the parasites as well as information on gene ex- 
pression. 	Investigations at the level of the 'gene' could provide 
conclusive evidence for the basis of drug resistance. 	In addition, 
genes which code for antigens could be found and cloned which would be 
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of value for vaccine production. Such aims are probably ambitious 
but nevertheless this approach is still a valid one. 
It would be naive to believe that the malaria situation will not 
persist or even get worse as chloroquine-resistant strains of P. 
falciparuin continue to develop and spread throughout the endemic regions 
of the world. 	The development of malaria vaccines against various 
stages of the parasite is a long term project, although studies indicate 
that this is theoretically feasible (Cohen, 1979; Murphy, 1979; 
Murphy & Lefford, 1979). 	Should such vaccines be developed, it would 
take many years before their application is widespread. 	At present, 
where even the production and marketing of a new drug, such as meflo-
quine, is viewed as uneconomic, the chance of an expensive vaccine 
reaching the countries affected by the disease in the immediate future 
is small. 	If such a vaccine were developed, its manufacture and ad- 
ministration would require international support and cooperation. 
Chemotherapy, therefore, is likely to remain as the practical 
treatment against malaria for the foreseeable future. 	Research on 
the nature of drug interaction, the fate of drugs, in hosts and para-
sites, on drug action and mechanisms and the genetics of drug resist- 
ance are therefore essential. 	Such studies are especially important 
with existing drugs such as chloroquine and potentially promising 
drugs such as mefloquine. 	It is hoped that this investigation has 
helped to elucidate some of the questions about resistance to these 
two drugs and hence contribute to the solving of the malaria problem. 
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TABLE 34: Calculation of Standard Error Estimates 
Standard Error =Fn 
-2 
Where 2 






is the mean 
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TABLE 35: 	Drug Delay Test Using 10 mg kg 1 Chlorogujne 
S 
% Parasitaemja 	± S.E.) 
Day of Infection D3 D4 D5 D6 D7 D8 ......D13 D15 
Drug Treatment I 
AS(SENS) DG 0.07 - - - 0.06 0.08 
(±0.04) 
- 
(±0 . 06 ) (±0 . 06 ) 
UND 0.06 0.5 




50(±0) PP PP PP 
AS(3CQ) DG 0.5 0.3 0.1 1.3 
03) (±0.07) - - - 
- (-+0.08) (±0.2) 
UND 0.4 1. 8 10.0 41.0 
(±0 . 035) (±0 . 3 ) (±3 . 6 ) (±7 . 4 ) 
PP PP PP PP 
AS(15CQ) DG 0.2 0.3 0.05 0.05 3.7 0.8 
±0 . 07) (±0 .2) (±0.03) - - (±0 . 01) (±1 . 02 ) (±0 . 3 ) 
UND 0.4 3.1 19.7 49.7 
(±0 . 15) (±0 . 4) (±4 . 6) (±. 4) 
PP PP PP PP 
AS(30CQ) DG 0.6 1.2 1.3 1.2 0.9 2.6 0.9 0.1 
(±0 . 07) (±0 . 5) (±0 . 3) (±0 . 5) (±0 . 3) (±0 . 9) (±0 .7) (±0 .06) 
UND 0.6 3.2 16.9 43.3 8.3 (jo.is) (±0 . 7) (±.•) (±2 . 9) (±1 .5) 
PP PP PP 
DG: Drugged animals - mean of 3 mice; drug administered on D3 - D6 
UND: Undrugged animals - mean of 4 mice 
PP: Post Peak 




















(±0 . 09 ) 
PP 
0.7 
(±0 . 5 ) 
PP 
TABLE 36: Drug Delay Test Using 20 mg kg 1 QilorQguine 
% Parasjtaemja (± S.E.) 
L Day of Infection 	D3 	D4 	D5 	D6 	D7 	D8 ...... D13 	D15 
Drug Treatment 





(±0 . 07 ) 
2.8 
(±0 . 5 ) 
114 . 
(±. 3 ) 
50(±0) PP 
AS(3CQ) DG 0.6 - - - - 
UND 0.4 




(±7 . 4 ) 
PP PP 
AS(15CQ) DG 0.2 0.05 0.06 0.07 0.1 
(±0 . 12 ) (±0.03) (±0 . 06 ) (±0.06) - (±0.1) 
UND 0.4 3.1 19.7 49.7 PP PP (±0 . 2 ) (±0 . 4 ) (±4 . 6 ) (±3 . 4 ) 
AS(30CQ) DG 0.8 0.9 0.5 0.5 1.0 3.8 
(±0.09) (±0.2) (±0.1) (±0.09) (j0.1) (+1.6) 
UND 0.5 3.2 16.9 43.3 83.0 PP 
(±0 . 2 ) (±0.6) (±3.5) (±2.9) (±2.9) 
DG: Drugged animals - mean of 3 mice; drug administered on D3 - D6 
UND: Undrugged animals - mean of 4 mice 
PP: Post Peak 
Legend as for Figure 10 
I-. 
TABLE 37: Response of Different Lines of P. chabaudj to Varying Doses of CQ 
% Parasitaernja(± S.E.) 
Drug Dose 
UND 
(mg kg- for 6 days)  3CQ 5CQ iocQ 
Day of Infection D7 D5 D7 D9 D5 D7 D9 D5 	D7 D9 
Run I 
AJ(SENS) 44.2 0.05 0.7 9.9 
- 
0.008 
±14 . 0 ) (±. 025 ) (±3 . 6) 40.008) - - 
AS(3CQ) 38.0 9.1 34 PP 0.07. 0.6 6.8 
(±16 . 5 ) (±6 . 2 ) (-±22 . 5 ) (-1-0.05) (±0.4) (±4.) 
- 	- - 
AS(15CQ) 39.0 2.8 20.5 17.5 0.08 1.8 15 0.005 - 0.4 
(±11 . 3) (±1 . 7) (±. 0) (±2 . 7) (±0 . 08) (±1 . 5) (±8 . 9) (±0 . 003)(±0 . 2 ) 
AS(30Q) 54.0 8.0 40.5 PP 0.2 7.0 18.1 0.01 	0.2 6.5 
(±2 . 6 ) (±2 . 4) (±8 . 4 ) (±6. 2 ) (±2 . 8 ) (±4 . 2 ) (±0 . 006)(+0 .00e)(+2.6) 
Run II 
AJ(SENS) 50.0 2.9 34.0 pp 0.1 0.5 8.3 
(±O (±1 . 7 ) (j8.0) (-o.1) (-0.3) (±4 . 5 ) - 	- - 
AS(3CQ) 45 2.4 18.1 PP 0.4 
. 
2.5 25.3 
(±2.5) (±1 . 2 ) (±8 . 1 ) (±o.oe) (±0.5) 41.6) - 
AS(15Q) 52 3.3 17.7 PP 1.1 7.6 37.5 0.2 5.8 (±1.0) (±1.3) (±2.8) (±0.3) (±2 .2) (±4.3) - 	(±0 . 08 ) (±2.3) 
AS(30Q) 32.0 4.8 31.8 PP 1.2 16.6 38.8 0.005 0.3 2.8 (±13.0) (±1.8) (±5.5) (±0.2) (±3.5) (±6 . 8 ) (±0 .003 )(±O.3) (±2 . 0 ) 
Drugged animals - mean of 4 mice 
UND: Undrugged animals - mean of 3 mice 
144. 
TABLE 38: Drug Tests of Stability Studies on the AS(30CQ) Line 
% Parasjtaemia (+ S.E.) 
Drugged Undrugged 
Day of Infection D9 D10 	D11 D13 D15  
Experiment No. 
i) AS(30CQ) 0.04 1.0 Pp 
(±0 . 01 ) (±0 . 14 ) 
AS (3CQ) CONTROL - 16.0  
- (+1.0) 
 AS(3OCQ) 0.008 0.2 3.4 50.0 
 (±0.02) (±0.9) 
AJ(Sens) CONTROL - 45.0 
 - (±0) 
 Passage No.1 
AS(30CQ) 0.09 0.82 22.0 
- (±o.°') (±0 . 2 ) (±s.o) 
AS(3CQ) CONTROL - - 42.0 
- (±14 . 84) 
 Passage No.5 
AS(30CQ) 0.05 0.5 0.8 42.5 
(±0 . 035) (±0 . 3 ) (±0 . 4) (±2 . 5 ) 
AS(3CQ) CONTROL - - - 42.0 
- (±0 ) 
 Passage No.6 
AS(30CQ) 0.02 0.5 30.0 
(±0.01) (±0.4) (±9.9) 
AS(3CQ) CONTROL - 45.0 
 - (±5.0) 
 Passage No.8 
AS(30CQ) 0.006 0.3 4.2 
.006) 
(±0. 1) (±3.9) 
AS(3CQ) CONTROL - 50.0 
- (±0 ) 
 AS(3oCQ) 0.03 0.2 3.2 20.0 
- (±0. 01 ) (4_0 . 05 ) (±1.6) (±5.0) 
AJ(Sens) CONTROL - - - 50.0 
- (±0 ) 
 A5(30CQ) 0.006 0.014 0.6 2.9 45.0 
(±0.006) (±0.01) (±0.3) (±1.0) (±0) 
AJ (Sens) CONTROL - - - 40.0 
- (±0) 
Drugged animals - mean of at least 3 mice, treated with 30 mg ' 
for 6 days 
Undrugged animals - mean of 2 mice 
Legend as for Figure 11 
145. 
TABLE 39: Stability of AS(3OMF) Line After Mosquito Transmission 
% Parasitaemia(± S.E.) 
Day of Infection D9 	D11 	D13 	D15 UND D9 
A3(30MJ') (Before MOS) - 	
0.09 	0.3 	1.5 pp 
(±0 . 03 ) 	(±0 . 1 ) 	(±0.5) 
A5(30MF) (After MOS) MI - 	- 	- 	- PP 
Mil - pp 
MOS - Mosquitoes 
Drugged animals - mean of mice treated with 30 mg k9- 1 
mefloquine for 4 days 
UND - Undrugged animals 
PP - Post Peak 
Legend as for Figure 13 
146. 
TABLE 40: Stability of AS(3OMF) Line 
% Parasjtaemia(+ S.E.) 
Day of Infection D9 	D11 D13 D15 UND D9 
AS(3OMF) Before MOS 0. 4 	5. 3 10 . 1 PP PP 
(±0 . 2) 	(±2 . 6) (±4 . 0) 
AS(30MF) After 1 MOS 0.2 0.5 1.7 
PASSAGE (±0 . 07) (±0 . 2) (±0 . 7) 
PP 
AS(3OMF) After 2 MOS 
PASSAGES - 	 - - - PP 
AS(30CQ) - 	 - - 
- PP 
MOS - Mosquitoes 
Drugged Animals - mean of 3 mice, treated with 15 mg kg- I 
mefloquine for 4 days 
UND - Undrugged animals 
PP - Post Peak 
Legend as for Figure 13 
147. 
TABLE 41: Mefloquine-Resistance of AS(30MF) After Mosquito Transmission 
% Parasitaemia(± S.E.) 
STABILATE NO. Day of Infection D12 	D14 	D16 UND D12 
PASSAGE NO. 
df 870 8 0.6(±2) pp 
9 0.2 PP 
(±0 . 08) 
15 - 	- 	0.2 
PP 
(±0 . 08) 
16 - 	- 	- PP 
df 900 4 - 	
0.1 	0.4(+0 1 ) 
(±0.05) 	- 
PP 
5 - 	 1.8(±0.5) PP 
Drugged Animals, mean of 3 mice, treated with 15 mg kg- 1  MF 
for 4 days 
UND - Undrugged Animals, mean of 2 mice 
PP - Post Peak 	- 
AS(15CQ) Line Control used in all tests showed negative 
infection throughout 
Legend as for Figure 13 
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mice infected with S. mansoni significantly more 
21-day-old schistosomula established in the portal 
system and chloroquine had a reduced depressive 
effect on the P. yoelii parasitaemia and recrudes-
cences occurred. 
Development of Trypanosoma congolense in tissue 
sites 
A. G. LUCKINS, A. R. GRAY AND J. GREENHORN 
Centre for Tropical Veterinary Medicine, University 
of Edinburgh 
Trypanosomes were found in connective tissue 
in local skin reactions developing in cattle, sheep 
and rabbits at the sites of bites by Glossina niorsitans 
infected with Trypanosoma congolense. The parasites 
developed in the collagen of the deep dermis and 
were particularly numerous in reactions examined 
up to 12 days after infection. Substantial numbers 
of trypanosomes were present at the reaction site 
in calves up to 21 days after infection and were still 
present 30 days after infection. The invasion of 
collagen by the parasites appeared to be focal and, 
from limited observations, there was no evidence 
that the infection in the connective tissue became 
generalized. 
Villous atrophy in the mouse: a thymus- 
dependent phenomenon 
D. F. MANSON-SMITH, R. G. BRUCE AND DELPHINE 
M. V. PARROTT* 
Departments of Zoology and *B acteriology  and 
Immunology, University of Glasgow, Glasgow 
G12 8QQ 
An analysis of the response of the small intestine 
to Trichinella spiralis infection in thymus-deprived 
NIH mice has shown that depletion of T-cells has a 
dramatic effect on the localization of adult worms 
in the small intestine and that normal expulsion 
does not occur. Villous atrophy and crypt hyper-
plasia which accompany the infection in normal 
mice is absent or reduced, especially in the jejunum, 
thus providing clear evidence that in this model 
villous atrophy is a thymus-dependent phenomenon. 
An in vitro test for chioroquine-sensitivity in 
Plasmodium chabaudi 
R. A. PADUA 
Institute of Animal Genetics, University of Edinburgh 
Rieckmann et al. (1978, Lancet, i, 22-33) have 
described an in vitro micro-test for assessing the 
chloroquine-sensitivity of strains, of P. falciparurn. 
A modification of this test has been applied to 
chioroquine-sensitive and resistant lines of P. 
chabaudi. In the absence of the drug, parasites of 
both lines matured to schizonts. At low chloroquine 
doses, the sensitive line showed delayed develop-
ment, schizonts being formed later than in un-
drugged controls. In the resistant line, vacuoles 
were seen in parasites exposed to chloroquine. 
Infectivity tests in mice showed that the resistant 
parasites were viable following incubation with 
chloroquine, while sensitive forms showed reduced 
viability. 
Mefloquine-resistance in Plasmodiu,n chabaudi 
R. A. PADUA AND D. WALLIKER - 
Institute of Animal Genetics, University of Edinburgh 
The activity of mefioquine against chioroquine-
resistant and sensitive lines of Plasinodium chabaudi 
has been examined. Using a standard four-da y test, 
two lines, one moderately resistant to chloroquine 
and one highly resistant, were found to be less 
sensitive to mefloquine than a chloroquine-sensitive 
line. A mefioquine-resistant line of P. chabaudi was 
developed by exposing sensitive forms to gradual 
increases in drug pressure during blood passage in 
mice. Following selection, a line resistant to 
mefioquine at .30 mg/kg (four doses) was produced. 
The resistance was moderately stable in the absence 
of the drug. 
We thank the Division of Medicinal Chemistry, 
Walter Reed Army Institute of Research, Washing-
ton, for supplying us with mefloquine. 
The effects of BCG organisms on the course of 
Plas,nodiuin chabaudi, P. berghei and Trypanosoma 
brucei infections in mice 
L. J. PANTON AND R. S. PHILLIPS 
Department of Zoology, University of Glasgow 
C57B1 and ,CBA male mice were injected intra-
venously (i.v.) with approximately 10 BCG 
organisms (Glaxo). The C57B1 mice along, with 
controls were subsequently challenged two, three, 
four or eight weeks later with either lOi Plasmodium 
chabaudi (AS strain ) or 10 Plasmodiumn berghei 
(KSPI1 strain) parasitized red cells. The CBA mice 
were challenged with lO Trypanosoma brucei 
(TREU 792) two, three, four or eight weeks after 
BCG.-- 
The C57131 mice showed some protection against 
P. chabaudi two and three but not four and eight 
weeks after BCG. In mice challenged with P. berghei 
after BCG the early patent parasitaemias were 
higher in the BCG-treated mice and those mice 
injected at four and eight weeks died before the 
relevant controls. In all the CBA mice the BCG 
depressed the early T. brucei parasitaemias and 
delayed death. 
Cryopreservation of Plasmodium falciparumn in 
liquid nitrogen 
R. S. PHILLIPS*  AND R. J. M. WrLsoNt 
*Department  of Zoology, University of Glasgow, and 
t National Institute for Medical Research, London 
NW7 IAA 
Human red cells containing ring stages of 
Plasmodiwn falciparum were washed with medium 
199 (PHiLLII's et al., 1972, Parasitology, 65, 525), 
resuspended in Caucasian serum and cryopreserved 
(total volume 05 ml) in either glycerol in phosphate 
buffered saline (PBS) (final concentration 17, v /v) 
or dirnethyl suiphoxide (DMSO) (final concentra-
tion of 10',,, 12',, and 15 v/v) by plunging 
Sterilin ampoules into liquid N9. Infected blood 
was thawed for 1 min at 37 ° C and the cryoprotectarit 
removed by five washings with ice-cold Sorbitol in 
PBS in which the concentration of Sorbitol was 
gradually lowered from 175 to zero. After a final 
washing in .199 the cells, resuspended in serum, 
British Society for Parasitology: Proceedings  
ning replicate groups of test animals which were infected at different intervals post-
unphintation, eliminating the possible complication of acquired immunity. At a drug con-
c..ntrat.ion of 05% pyrimethamine, protection from infection for > 5, < 6 months was 
achieved. 
Preliminary experiments using other antimalarials in combination with silicone rubber 
have been performed and the results may be summarized as follows. 
l'rinaquino diphosphate, cycloguanil HC1 and menoctone implants gave rise to local 
issue necrosis similar to that observed when these drugs are given by normal routes of 
administration. 
Chioroquirie implants were ineffective in contrast to those containing pyrimethamine 
i-ethionate, sulphadiazine and sulphormethoxine. 	- 
These results suggest that the administration of antimalarials in sustained-release delivery 
systems warrants further investigation. 
Genetics of Chioroquine Resistance in Rodent Malaria. By R. A. PADUA (Department 
of Genetics, University of Edinburgh, Edinburgh, EH9 3JN) 
Using Plasmodium clmabaudi, a rodent malaria parasite, the genetic basis of chioroquino 
resistance was examined. A high level of chloroquine resistance (30 rag/kg for 6 days) was 
established by gradual increases of drug pressure. This resistance was stable after multiple 
blood passages and mosquito transmission. The inheritarce of the cliloroquine resistance was 
examined by crossing the resistant line to the sensitivo line. The progeny of the cross were 
cloned and tested for drug response. The clones were classified as being either sensitive, 
intermediate (resistant to either 3 mg/kg or 15 mg/kb for 6 days), or highly resistant 
(30 mg/kg for 6 days). As there are intermediate levels of resistance resmmlt-ing 1 from tho cross, 
time high level of resistance can be concluded to be the result of more t.lia,t one mutation. 'J'his 
system may be a model for the different typos of chioroquino response observed in the lumnimuk 
malaria parasite P. falciparurn. 
SESSION lB 
Hel,ninth ultrastructure 
The Tegumental Surfaces of Some Species ofthe Genus Paramplmisto:numfischoeder, 
1901, as Revealed by Scanning Electron Microscopy. By L. ErwAitno (Common. 
wealth Instil te of Hthnint/tology, The White House, 103 St 1ctcr's .treet, St Albans, 
liens, EnglanAL1 3EW) 
Eleven species of Paramphistomum from ruminants were examined for surface structures. 
Most revealed the presence of structures termed here surface 'papillae'. It was observed that 
there exist some differences as to occurrence, distribution and size of theso structures among 
the species examined but theso appear to be consistent in the same species of different ages 
and froni different hosts. - - - 
On time basis of occurrence, distribution and size of these surface p;ipillae, it is possible to 
separate the eleven species examined into four groups as follows: Group 1 - absence of surface 
papillae, e.g. Para;nphmistomumn cervi; Group 2 - presence of surface papillae limited only 
around the anterior end, e.g. P. gracile, P. clavula, P. ichikawai; Group 3—surface papillae 
densely arranged around the anterior end and ventrally around the genital pore area, but the 
sizq of these papillae in the two areas differs, e.g. P. mnicrobothnioicla', P. sukani; Group 4 - 
surface papillae densely arranged around the anterior end and around genital pore area which 
aroof-the same structure and almost of the same size, e.g. P. gotei, 11 . leydeni, P. scotiae, 
P. microboghrium, P. epiclitum. 
A key to separatd these species on the basis of tegumental and internal pharyngeal surface 
structures together with histo-morphological features is given. 
Cyst Structure and Excystment of Asymphylodora doilfusi Metacercariae. By N. A. 
EVANS (King's College London) 
Metacercariae of Asy;nphylodora doilfusi excyst and develop into gravid parasites in the 
pericardial cavity of certain second intermediate hosts (the prosobranch molluscs Bithynia 
- 	 30-2 
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